


**British Association of Dermatologists  
93rd Annual Meeting**

**ACC Liverpool  
9th – 11th July 2013**



**LIVERPOOL 2013**

**Final Programme**

# LEO Pharma sponsored satellite symposium: Picato<sup>®</sup>, Actinic Keratosis (AK)\* and the Patient

\*Picato<sup>®</sup> is licensed for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.



## The 93rd Annual Meeting of the British Association of Dermatologists, ACC Liverpool

18:15 – 19:00, Wednesday 10th July 2013, Hall 3B

Come and join this evening meeting to discuss current challenges surrounding the management of actinic keratosis and how Picato<sup>®</sup>, a new treatment for actinic keratosis\*, may help to improve the management of your patients.

This interactive symposium will be chaired by Dr John Lear, Consultant Dermatologist, Manchester Royal Infirmary and Hope Hospital, Salford, and will review current treatments and clinical data for Picato<sup>®</sup>. The patient experience will also feature.

Time	Session	Speaker
18:15	Current therapies for AK patients in the UK	Dr John Lear, Consultant Dermatologist, Manchester Royal Infirmary and Hope Hospital, Salford
18:25	Picato <sup>®</sup> within AK* treatment	Dr Sandeep Cliff, Consultant Dermatologist and Dermatological Surgeon, East Surrey Hospital, Surrey and Sussex Healthcare NHS Trust
18:40	The Picato <sup>®</sup> patient experience	Dr Tony Downs, Consultant Dermatologist, Royal Devon and Exeter NHS Foundation Trust
18:55	Question and answer session	Dr John Lear

### Abbreviated Prescribing Information for Picato<sup>®</sup> 150 micrograms/gram (mcg/g) and 500 micrograms/gram (mcg/g) gel

**Presentation:** Picato<sup>®</sup> 150 micrograms/gram (mcg/g) gel: each gram of gel contains 150 mcg ingenol mebutate; each tube contains 70 mcg ingenol mebutate in 0.47 g of gel. Picato<sup>®</sup> 500 mcg/g: each gram of gel contains 500 mcg ingenol mebutate; each tube contains 235 mcg ingenol mebutate in 0.47 g of gel.

**Indication:** Cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.

**Dosage and administration:** Application to the face and scalp (150 mcg/g): One tube to be applied once daily to affected area for 3 consecutive days. Application to the trunk and extremities (500 mcg/g): One tube to be applied once daily to affected area for 2 consecutive days. *Paediatrics:* No relevant use. *Elderly:* No dose adjustment required. The contents of one tube covers a treatment area of 25 cm<sup>2</sup> (eg 5 cm x 5 cm); this should be applied to one treatment area of 25 cm<sup>2</sup>. Tube for single use only; discard after use. Squeeze the gel from the tube onto a fingertip and spread evenly over entire treatment area, allowing to dry for 15 minutes. Treatment of neck: if more than half of the treatment area is located in the upper part of the neck, posology for face and scalp should be used. If more than half of the treatment area is located in the lower part of the neck, posology for trunk and extremities should be used. Wash hands with soap and water immediately after applying gel. If treating hands, patients should only wash fingertip used to apply the gel. Avoid washing and touching treated area for 6 hours after applying gel. After this period, treatment area may be washed using mild soap and water. Gel should not be applied immediately after taking a shower or less than 2 hours before bedtime. Treated area should not be covered with occlusive bandages after applying gel. Optimal therapeutic effect can be assessed after approximately 8 weeks. If treated area shows an incomplete response at follow-up, treatment should be carefully re-evaluated and management reconsidered. Clinical data on more than one treatment course of 2 or 3 consecutive days not available. Clinical data on treatment of more than one area not available. Treatment in immunocompromised patients not available, but systemic risks not expected since ingenol mebutate is not absorbed systemically.

**Contraindications:** Hypersensitivity to any of the constituents.

**Precautions and warnings:** Avoid contact with eyes. If accidental exposure occurs, flush eyes with large amounts of water and seek medical care as soon as possible. Eye disorders such as eye pain, eye lid oedema and periorbital oedema expected to occur after accidental exposure. Gel must not be ingested. If accidental ingestion occurs, drink plenty of water and seek medical care. Administration not recommended until skin healed from treatment with any previous medicinal product or surgery. Do not apply to open wounds or damaged skin. Do not use near the eyes, inside nostrils, inside ears or on lips. Local skin responses (LSRs) such as erythema, flaking/scaling and crusting should be expected to occur after application. LSRs are transient and typically occur within one day of treatment initiation and peak in intensity up to one week following completion of treatment. LSRs typically resolve within 2 weeks of treatment initiation when treating face and scalp and within 4 weeks of treatment initiation when treating trunk and extremities. Treatment effect may not be adequately assessed until resolution of LSRs. Ingenol mebutate did not demonstrate any potential for photo irritation or

photo allergic effects during studies to assess the effect of UV irradiation. However, due to nature of disease, excessive exposure to sunlight (including sunlamps and tanning beds) should be avoided or minimised. Clinically atypical lesions or suspicious lesions for malignancy should be biopsied to determine appropriate treatment.

**Drug interactions:** Interactions with systemically absorbed medicinal products considered minimal as gel not absorbed systemically.

**Pregnancy and lactation:** No data from use of ingenol mebutate in pregnant women. Animal studies showed slight embryo-foetal toxicity. Risks to humans receiving cutaneous treatment with ingenol mebutate considered unlikely as no systemic absorption. As a precautionary measure, it is preferable to avoid use of the gel during pregnancy. No effects on the breast-fed newborn/infant anticipated. Instruct nursing mother that newborn/infant should avoid physical contact with the treated area for 6 hours after application of gel.

**Side effects:** Most frequently reported adverse reactions (AEs) are LSRs. Following application of ingenol mebutate, most patients (>95%) experienced one or more LSRs. *AEs observed for face and scalp (150 mcg/g):* Very common: Application site: pustules, erosion, vesicles, swelling, exfoliation, scab, erythema, pain. *Common:* Headache, eye lid/periorbital oedema, application site: infection, pruritus, irritation. *Uncommon:* Eye pain, application site: discharge, paraesthesia, ulcer.

*AEs observed for trunk and extremities (500 mcg/g):* Very common: Application site: pustules, erosion, vesicles, swelling, exfoliation, scab, erythema. *Common:* Application site: pain, pruritus, irritation. *Uncommon:* Application site: paraesthesia, ulcer, warmth.

**See SmPC for a full list of side effects.**

**Legal category:** POM.

**Product Licence Number and Holder:** Picato<sup>®</sup> 150 mcg/g gel - EU/1/12/796/001;

Picato<sup>®</sup> 500 mcg/g gel - EU/1/12/796/002. LEO Pharma A/S, Ballerup, Denmark.

**Basic NHS Price:** Picato<sup>®</sup> 150 mcg/g gel, 3 x 0.47 g, £65.00; Picato<sup>®</sup> 500 mcg/g gel, 2 x 0.47 g, £65.00

**Last revised:** November 2012. © Registered Trademark

**Adverse events should be reported. Reporting forms and information can be found at: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Drug Safety at LEO Pharma by calling 01844 347333.**

LEO<sup>®</sup> all LEO trademarks mentioned belong to The LEO Group

Further information can be found in the Summary of Product Characteristics or from: LEO Pharma, Longwick Road, Princes Risborough, Buckinghamshire, HP27 9RR, UK



Job Code: 4340a/00136b Date of preparation: May 2013

## INDEX

	PAGE NUMBER
Accompanying persons	6
App	6
Additional meetings	12
Badges	6
Banking	6
Business Services	6
Catering	6
Certificates of attendance	6
Cloakroom	6
Committee meetings	11
Continuing Professional Development (CPD)	6
Exhibition	6
Exhibitor Directory	64 - 71
Exhibition quiz	6
Exhibition Plan	62 - 63
First aid	6
Focus Sessions	51
Map of Liverpool	72
Meetings Calendar	73
Messages	6
Organising Committees	4
Parking	7
Patient support groups	7
Payment of registration fees	7
Poster exhibition	7
Posters	53 - 57
Registration desk	7
Restaurants	7
Satellite Symposia	58 - 61
Social events	10
Speaker preview	8
Special interest groups	8
Taxis	8
Transport - to and from Liverpool	8
Venue Plan	9
Welcome to Liverpool	5
Programme index	14

	PAGE NUMBER
<b>MONDAY OVERVIEW 15</b>	
Dermatopathology Self Assessment	16
Trainee pre-conference session	17
SAS Session	18
<b>TUESDAY OVERVIEW 19</b>	
CPCs - Joint BAD / BSD	20 - 21
Plenary Session pm	21 - 22
British Society for Skin Care In Immunocompromised Individuals (BSSCI)	23 - 24
British Teledermatology Society (BTS)	25
British Society of Cutaneous Allergy (BSCA)	26 - 27
British Society for Paediatric Dermatology (BSPD)	28 - 30
Historical	31 - 32
British Society for Dermatopathology (BSD)	33 - 35
<b>WEDNESDAY OVERVIEW 37</b>	
Plenary session am	38
Understanding Pharma	39
Plenary session - Medical Dermatology	40
BAD and BDNG Joint Meeting	41
British Society for Dermatological Surgery (BSDS)	42 - 45
British Photodermatology Group (BPG)	46 - 47
<b>THURSDAY OVERVIEW 49</b>	
Plenary Session Professor's & Registrars' forum	50 - 51
Focus Session	50
CPD update	52
<b>KEYNOTE LECTURES</b>	
<b>Tuesday</b>	
Professor Chris Denton	22
Professor Wendy Reid	22
<b>Wednesday</b>	
Professor Irwin Mclean	38
<b>Thursday</b>	
Professor Richard Gallo	51
Professor Nicholas Soter	52

### CONFERENCE & EVENT SERVICES

Mr Chris Garrett - Conference & Event Services Manager  
 Mrs Jenna Bowler – Senior Events Coordinator  
 Mrs Marie Elwér – Finance and Conference Officer  
 Miss Sally-Ann Koomson – Marketing & Events Coordinator  
 Miss Danielle Bailey – Events Coordinator

### ORGANISING COMMITTEE

Miss Marilyn Benham  
 Mrs Jenna Bowler  
 Prof Chris Bunker  
 Dr David Eedy  
 Mr Chris Garrett  
 Mrs Catherine Hanaway  
 Dr Shaheen Haque-Hussain  
 Prof Eugene Healy  
 Dr Glenda Hill  
 Dr Jane McLelland  
 Prof Malcolm Rustin - Chair  
 Dr Graham Sharpe

### BAD ABSTRACT SELECTION COMMITTEE

Dr Michael Ardern-Jones  
 Dr David Eedy  
 Prof Eugene Healy  
 Dr Eduardo Calonje  
 Dr Paul Craig  
 Dr Lynne Jamieson  
 Dr Jane McLelland  
 Dr Catherine Orteu  
 Prof Malcolm Rustin - Chair  
 Dr Graham Sharpe  
 Dr Graeme Stables  
 Dr Saleem Taibjee

### BAD JUDGING COMMITTEE

Dr Emma Benton  
 Dr Daniel Creamer  
 Dr Louise Fearfield  
 Dr Hiva Fassihi  
 Dr Claire Fuller  
 Dr Mark Griffiths  
 Dr Catherine Harwood  
 Dr Ferina Ismail  
 Dr Janakan Natkunarajah  
 Dr Catherine Orteu - Chair  
 Dr Olivia Schofield  
 Dr Victoria Swale

### BPG ABSTRACT SELECTION COMMITTEE

Dr Richard Dawe  
 Dr Chris Edwards  
 Prof James Ferguson  
 Dr Victoria Goulden  
 Prof John Hawk  
 Dr Helen Menage  
 Dr Ljubomir Novakovic  
 Dr Robert Sarkany

### BSCA ABSTRACT SELECTION COMMITTEE

Dr Helen Horne  
 Dr Sarah Wakelin  
 Dr Mark Wilkinson

### BSPD ABSTRACT SELECTION COMMITTEE

Dr Susannah Baron  
 Dr Fiona Browne  
 Dr Jane Ravenscroft  
 Dr Hossain Shahidullah

### BSD ABSTRACT SELECTION COMMITTEE

Dr Eduardo Calonje  
 Dr Paul Craig  
 Dr Lynne Jamieson  
 Dr Saleem Taibjee

### BSDS ABSTRACT SELECTION COMMITTEE

Dr Colin Fleming  
 Dr Vindy Ghura  
 Dr David Harris  
 Dr Raj Mallipeddi  
 Dr Graeme Stables

### BSSCII ABSTRACT SELECTION COMMITTEE

Dr Catherine Harwood  
 Dr John Lear  
 Dr David Paige  
 Dr Bill Phillips  
 Prof Charlotte Proby  
 Dr Helen Ramsay

### BTS ABSTRACT SELECTION COMMITTEE

Dr Carolyn Charman  
 Dr Saul Halpern  
 Dr Colin Morton

### HISTORICAL ABSTRACT SELECTION

Dr Peter Copeman  
 Dr David Eedy  
 Dr Julia Ellis  
 Dr Frances Humphreys  
 Dr Nick Levell  
 Dr Sid Orpin  
 Dr Rakesh Patalay  
 Dr Paul Yesudian

### ACKNOWLEDGEMENTS

The British Association of Dermatologists gratefully acknowledges the contribution of the many exhibitors & sponsors whose attendance has helped make the meeting possible.

## A WARM WELCOME TO LIVERPOOL 2013

Welcome to Liverpool for the 93rd Annual meeting of the British Association of Dermatologists. Thank you for registering, we hope you have an enjoyable meeting. Once again we are in the award winning Liverpool Arena and Convention Centre, located in the world-famous Liverpool waterfront. Liverpool is a diverse and exciting city with a huge range of attractions, hotels and restaurants in close proximity to the conference centre. Situated in the heart of the city on the historic, world-heritage waterfront, the Liverpool Arena and Convention Centre is a state-of-the-art conference venue offering all the space, facilities and professional service to satisfy the needs of our delegates and exhibitors, making it the ideal location to stage a successful Annual Meeting.



### Scientific Programme

The annual meeting committee has again worked hard to provide a blend of new scientific presentations with updates from experts in various fields.

We are pleased to announce that the Arthur Rook Oration will be delivered by Professor Richard Gallo from San Diego, USA. Professor Chris Denton from London will give the first of the guest lectures at the plenary session on Tuesday speaking on Scleroderma. He will be followed later that afternoon by Professor Wendy Reid, Medical Director of HEE, who will talk about 'Health Education England - the new structure for education and training in the NHS'. Wednesday's programme features Professor Irwin McLean who will update the BAD membership on inherited skin barrier defects in atopic eczema. The final guest lecture will come from Professor Nicolas Soter, Professor at New York University School of Medicine, who will talk during the CPD session on Thursday afternoon on 'A Current Therapeutic Armamentarium for Chronic Idiopathic and Autoimmune Urticaria/Angioedema'.

For those who did not attend the International Investigative Dermatology meeting in Edinburgh we have asked the authors of the two top scoring abstracts from UK training dermatologists to present their data at the Professors and Registrars forum.

On Monday 8th July we will be holding pre-conference sessions for trainees, Specialty & Associate Specialist doctors, medical students and there will be a BSD self assessment session.

We will have a new session on Wednesday morning titled 'Understanding Pharma'. All the Satellite Symposia will take place on Wednesday, with the focus sessions on Thursday lunchtime, featuring topics on Genital Dermatology, Dermoscopy and Clinical Services Issues.

Medical Dermatology features strongly in the programme with a dedicated session on Wednesday afternoon. Professors Brian Kirby, Lesley Rhodes and Frank Nestle will be presenting at the Professors and Registrars plenary forum on Thursday morning, with the popular CPD session taking place in the Thursday afternoon slot.

### Social Programme

The Welcome Reception will be held at the ACC Liverpool venue, offering a chance for all attendees and exhibitors to meet on the opening evening of the Annual Meeting. The reception will be situated in the Galleria beginning after the final session finishes at 18:00 and will leave time for attendees to dine afterwards.

The Annual Dinner will be held in St George's Hall in the centre of the city. St Georges Hall is widely regarded as one of the finest neo-classical buildings in the world and will provide a magnificent venue for the event.

We hope you have a great meeting, please do not forget the on-line evaluation survey, your views and feedback are crucial to planning of future meetings. Thank you to all our speakers, exhibitors and delegates for all adding to the anticipated success of the meeting.

Enjoy!

**Malcolm Rustin**  
**Academic Vice President (2011-2013)**



### ACCOMPANYING PERSONS

We regret that neither accompanying persons nor children/babies are permitted entrance to the exhibition areas, sessions or social events.

### APP

We are pleased to announce that we will be providing a smartphone conference app for delegates to use during the conference.

The app will provide the following features;

- Real time polling during sessions
- Ask the speaker a question
- Take notes on sessions
- Provide session feedback
- Full agenda details
- Speaker profiles
- Social Media
- Sponsor and exhibitor listings

Now is a great time to get the conference app on your mobile device. To access the app simply open your Smartphone browser and enter the following

URL: [www.bad2013app.org](http://www.bad2013app.org) or scan this QR Code



*BAD 2013 is grateful to Janssen for the sponsoring this app*

### BADGES

Conference badges will be handed to delegates on registration. For security purposes name badges must be worn at all times throughout the meeting. In the event that you lose your badge, a replacement must be obtained at the registration desk immediately.

### BANKING

A Barclays cash machine is situated on site, on the riverside of the building. Walk down the steps before the exit and the machine is on the left; there is no charge for using it.

### BUSINESS SERVICES

The E.On Business Centre offers various services, including photocopying, faxing, workstation hire, courier services and sale of stationery and various Liverpool souvenirs.

### CATERING

Lunch and all scheduled refreshment breaks will be served from designated points in the exhibition area, Hall 2 of the ACC. If the nearest catering point is not open, staff will direct you to the next most convenient point.

### CERTIFICATES OF ATTENDANCE

Certificates of attendance will be in your registration envelope.

### CLOAKROOM

There is a cloakroom located on either side of the Galleria. There is a charge of £1 per item. Guests will also be able to store luggage on the day of departure.

### COMMITTEE MEETINGS

A programme of the scheduled committee meetings can be found on page 11.

### DEVELOPMENT CREDITS (CPD)

This event will be approved for External credit for the CPD Scheme of the Federation of Royal Colleges of Physicians of the UK. Physicians should record their credits in their diaries, in accordance with the current RCP recommendations. Participants should only record the number of hours they attended. The main meeting has been approved for 18 credits and the CPD code is 80200.

### EXHIBITION

The exhibition will be located in Hall 2 of the ACC and will be open at the following times:

Tuesday 9th July	10:00 – 17:30
Wednesday 10th July	08:30 – 17:30
Thursday 11th July	08:30 – 15:30

### EXHIBITION QUIZ

Exhibition quiz forms will be included in delegate bags. To participate in the quiz, delegates must visit each participating exhibitor and answer a simple question. Participants must also obtain 4 answers from the patient support groups, please note you only need 4 from any of the Patient Support Groups present over the duration of the meeting. All completed quiz forms must be returned to the registration desk by 14:00 on Thursday 11th July. The prizes will be announced after the meeting.

### EXHIBITORS

Please see page 62 for a full list of exhibitors and an exhibition plan.

### FIRST AID

The stewards at the venue will be able to assist you.

### FOCUS SESSIONS

All 13:15 – 14:00 Free of charge, but do not include a sandwich bag.

#### Thursday 11th July

- Genital Dermatology
- Dermoscopy
- Clinical Services Issues

### MESSAGES

A delegate notice board will be situated adjacent to the registration desk, where all delegates' messages will be displayed.

### PARKING

The nearest car park to ACC Liverpool is the 1,600 multi-storey car park which is on site.

The 1600 space multi-storey Liverpool Waterfront Car Park is fully secure and open 24 hours a day, 7 days a week. It is centrally located on Kings Dock at the site of the ACC Liverpool.

### PATIENT SUPPORT GROUPS

The following patient support groups will be represented at the meeting and will have stands in the Hall 2:

#### Tuesday 9th July & Wednesday 10th July

- Caring Matters Now
- Ehlers Danlos UK
- Golin Syndrome Group
- Skin Camouflage Network
- Xeroderma Pigmentosum Support Group

#### Wednesday 10th July

- Psoriasis & Psoriatic Arthritis Alliance

#### Wednesday 10th July & Thursday 11th July

- Behct's Syndrome Society
- Latex Allergy Support Group

#### Tuesday 9th July, Wednesday 10th July, Thursday 11th July

- Alopecia UK
- British Association of Skin Camouflage
- Changing Faces
- Ichthyosis Support Group
- Nodular Prurigo International
- SKCIN
- The Hyperhidrosis Support Group
- The Psoriasis Association
- UK Dermatology Clinical Trials Network
- Vitiligo Society
- Worldwide Lichen Sclerosus

#### Thursday 11th July

- Skincare Cymru

**In addition, the following groups will have stands within the exhibition:**

- BADBIR
- BAD Communications
- British Skin Foundation
- BAD Journals
- Clinical Services Unit
- Community Dermatology & IFD
- Historical Collection
- 2014 World Congress on Cancers of the Skin
- Special Interest Groups

### PAYMENT OF REGISTRATION FEES

We would prefer delegates to pay by cheque (pounds sterling drawn on a UK bank only or by sterling bank draft) made payable to the 'British Association of Dermatologists'. Cheques in other currencies cannot be accepted. Alternatively, delegates may pay by credit card and this is encouraged for overseas delegates. Please note that we only accept MasterCard and Visa. **American Express cannot be accepted.**

### POSTER EXHIBITION

The poster exhibition will be located within the exhibition hall. The posters will be numbered and a list is provided on pages 53-57.

There will be an e-poster display area showing all the posters submitted. Posters should not be removed until 14:00 on Thursday 11th July. Please note that the British Association of Dermatologists cannot be held responsible for any loss or damage to a poster presented during the Annual Meeting.

### REGISTRATION DESK

The registration desk will be located on the Galleria level and will be staffed by the BAD team during the following hours:

Monday 8th July	09:30 – 18:00
Tuesday 9th - Thursday 11th July	08:00 – 18:00

### RESTAURANTS

For further information about local restaurants and bars around Liverpool please visit [www.visitliverpool.com](http://www.visitliverpool.com)

The ACC Liverpool Delegate Card will be made available to every delegate attending the conference and is packed with offers, discounts and privileges across a range of bars, restaurants, hotels and attractions throughout Liverpool.

### SATELLITE SYMPOSIA

The following companies will be holding satellite symposia at the meeting:

#### Wednesday 10th July

08:00 – 08:45	Hall 3A	Almirall
08:00 – 08:45	Hall 3B	Beiersdorf
13:15 – 14:15	Hall 11A & B	Meda
13:15 – 14:15	Hall 3A	AbbVie
13:15 – 14:15	Hall 3B	Janssen
18:15 – 19:00	Hall 3A	Novartis
18:15 – 19:00	Hall 3B	Leo Pharma







## VENUE



ACC Liverpool,  
Kings Dock,  
Liverpool Waterfront, L3 4FP

For Sat Nav, please use the postcode L3 4BX

T: +44 (0)151 475 8888  
Email: [info@accliverpool.com](mailto:info@accliverpool.com)  
[www.accliverpool.com](http://www.accliverpool.com)

## Wi-fi

There is wi-fi access throughout the ACC.  
Please search WiFi hotspots on your device and select free WiFi. You will then be automatically connected



## Key

- Lift
- Escalator
- Stairs
- Male/Female Toilets
- Disabled Toilets



## SOCIAL EVENTS

Please see Social Programme (Page 10).

## SPEAKER PREVIEW

Speaker preview will be located in Hall 6 & 7 on the upper level at the ACC, please ask at the registration desk for directions. All presenters **must** take their memory sticks to speaker preview at least **two hours** prior to their presentation. Data projection (PowerPoint) will be available.

## SPECIAL INTEREST GROUPS

The following Special Interest Groups will hold their meetings during the week of the conference. All special interest group meetings will take place in Liverpool. Their full programmes are featured at the back of each days full programme.

### Tues 9th July

British Society for Skin Care in Immunocompromised Individuals  
09:00 – 11:40 (Page 23 - 24)

British Teledermatology Society  
10:00 – 11:50 (page 25)

British Society for Cutaneous Allergy  
09:15 – 12:35 (Page 26 - 27)

British Society for Paediatric Dermatology  
09:00 – 12:30 (Page 28 - 30)

Historical  
11:00 – 12:30 (Page 31 - 32)

British Society for Dermatopathology  
15:00 – 18:00 (Page 33 - 35)

### Wednesday 10th July

British Society for Dermatological Surgery  
14:00 – 17:10 (Page 42 - 45)

British Photodermatology Group  
14:30 – 17:45 (Page 46-47)

## TAXIS

Black Cabs are often parked outside the ACC. The phone numbers of local taxi firms are: Davy Liver 0151 708 7080, Delta 0151 924 7373 and Village Cabs 0151 427 7909.

## TRANSPORT – IN AND AROUND Liverpool – TO AND FROM ACC Liverpool

[http://www.btconventioncentre.com/coming/find\\_us](http://www.btconventioncentre.com/coming/find_us)

### By Road

For all car journeys it's best to follow the white on brown tourist route signs for the Waterfront. These signs are visible on the major routes into the city. ACC Liverpool is situated on the Kings Dock directly adjacent to the south side of the Albert Dock. Upon arrival, the Kings Dock entrance is clearly sign posted.

### From the North

Leave the M6 at junction 26 and follow signs for M58 Liverpool. Follow to end of M58 and then take signs for A59 Liverpool. Continue to follow Liverpool City Centre until picking up signs for the Waterfront. The 1600 space multi-storey Liverpool Waterfront Car Park is signposted 'Waterfront' on the city wide 'available spaces' signage.

### From the South

Leave the M6 at junction 21A and take the M62 to Liverpool. At the end of the M62 follow signs for Liverpool City Centre along Edge Lane, picking up and following signs for Waterfront. The 1600 space multi-storey Liverpool Waterfront Car Park is signposted 'Waterfront' on the city wide 'available spaces' signage.

### By Air

Liverpool John Lennon Airport is just 8 miles from the city centre, and a 20 minute taxi ride to the ACC, with regular flights to Ireland and Europe. A taxi from the airport to the city centre will take approximately 20 minutes or the express bus service Route 500 will take approximately 25 minutes, dropping you off within a five minute walk of ACC Liverpool.

### By Rail

Liverpool is easily accessible by train from many other major towns and cities across the country, and can be reached in a journey time of just over two hours from London. ACC Liverpool is a 20-minute walk from Lime Street or a short taxi ride.



## SOCIAL EVENTS

### WELCOME RECEPTION

ACC Liverpool

Tuesday 9th July 18:00 – 20:00

The Welcome Reception will be held at the ACC Liverpool venue. Offering a unique chance for all attendees and exhibitors to meet on the opening evening of the Annual Meeting. Drinks and canapés will be served after the final session finishes at 18:00 and will leave time for attendees to dine afterwards.

The reception will take place on the Galleria, the spine connecting the arena and convention centre.



### ANNUAL DINNER

St George's Hall

Wednesday 10th July, 19:30

The Annual Dinner will be held in St George's Hall in the centre of the city. St Georges Hall is widely regarded as one of the finest neo-classical buildings in the world and will provide a magnificent venue for the event.



St George's Hall



## COMMITTEE MEETINGS

### MON 8TH JULY:

TIME	MEETING	ROOM
11:00 – 13:00	SAS Sub-committee	Hall 5
16:00 – 18:00	British Association of Dermatologists Officers	Hall 5
18:30 – 19:30	National Dermatology Trainee Committee	Hall 4B

### TUES 9TH JULY:

TIME	MEETING	ROOM
08:00 – 09:00	British Society for Dermatopathology Exec Committee	Hall 14
08:00 – 09:00	British Society for Paediatric Dermatology Training Committee	Hall 13
08:30 – 10:30	British Skin Foundation Grants Advisory	Hall 9
08:45 – 09:15	The British Society for Cutaneous Allergy (BSCA) AGM	Hall 1C
10:30 – 12:30	Dermatology Industry Group	Hall 11C
11:30 – 13:00	British Skin Foundation Trustees	Hall 13
11:40 – 12:10	British Society for Skin Care in Immunocompromised Individuals AGM	Hall 3B
12:00 – 14:00	Community Dermatology Editorial Board	Hall 8
13:00 – 14:30	Senior Skin Group	Hall 3B
13:30 – 14:30	Historical Collection Sub-Committee	Hall 9
14:00 – 15:30	Teachers of Undergraduate Dermatology	Hall 13
14:00 – 15:30	Health Informatics Sub-committee	Hall 5
14:00 – 17:00	British Society for Cutaneous Allergy Committee	Hall 12
14:30 – 15:00	British Society for Dermatopathology AGM	Hall 1C
16:00 – 17:00	Therapy & Guidelines Sub-committee	Hall 13
17:00 – 18:00	British Society for Paediatric Dermatology Committee	Hall 5
17:30 – 18:30	UK DCTN Trial Prioritisation Panel	Hall 9
17:30 – 18:30	BAD Session Judging Committee	Hall 14

### WED 10TH JULY:

TIME	MEETING	ROOM
08:00 – 09:00	Skin Cancer Prevention Sub-committee meeting	Hall 8
08:00 – 09:00	BJD Editorial Board Meeting	Hall 13
08:30 – 10:30	British Society for Medical Dermatology Committee	Hall 9
09:00 – 10:30	UKDCTN AGM/Steering Group	Hall 14
11:00 – 13:00	British Association of Dermatologists' AGM (Members Only)	Hall 1A
12:00 – 13:00	PUVA Guidelines Meeting	Hall 9
13:00 – 14:00	British Association of Dermatologists Officers	Hall 5
13:00 – 14:00	British Cosmetic Dermatology Group AGM	Hall 13
13:00 – 14:30	British Photodermatology Group Committee	Hall 8
13:15 – 14:15	Dermatology Forum for Wales Phototherapy sub-committee	Hall 4B
14:30 – 15:30	British Association of Dermatologists' Executive Committee	Hall 4A
14:30 – 18:00	BAD Session Judging Committee	Hall 14
17:30 – 18:00	UK Professors Group	Hall 8
17:10 – 17:45	British Society for Dermatological Surgery AGM	Hall 1C
17:45 – 18:15	British Photodermatology Group AGM	Hall 12

### THURS 11TH JULY:

TIME	MEETING	ROOM
08:30 – 09:30	Exhibitors' Meeting	Hall 13
09:00 – 12:00	British Society for Dermatological Surgery Committee	Hall 14
10:30 – 12:00	Specialised Dermatology Clinical Reference Group	Hall 13
13:00 – 14:00	BAD Session Judging Committee	Hall 14
13:00 – 14:30	World Congress on cancers of the Skin 2014 Programme Committee	Hall 13
14:30 – 15:30	World Congress on cancers of the Skin 2014 LOC	Hall 13




## ADDITIONAL MEETINGS

### TUES 9TH JULY:

TIME	MEETING	ROOM
13:00 – 14:30	Senior Skin Group For further information please contact <a href="mailto:maggie@kirkup.plus.com">maggie@kirkup.plus.com</a>	Hall 3A
16:30 – 17:30	Dermatology Teachers	Hall 3B
16:30	<b>Barriers and bridges: integrating dermatology learning into undergraduate programmes</b> Speakers: Dr Charlotte Reddick, Dr Lily Wheeler and Dr Mini Singh	
16:55	<b>How to make the most of the new BAD smartphone App for medical students.</b> Dr James Coleman and Dr Ingrid Helbling	
17:15	<b>Education update: what's been happening?</b> Dr Stuart Cohen	

### THURS 11TH JULY:

TIME	MEETING	ROOM
07:30 – 08:30	Christian Medical Fellowship If you would like to reserve a place at the breakfast please visit the on site registration desk.	Hall 4B



### Bringing together the best of the private and NHS worlds

Premium specialist reporting services by **a team of 10 dermatopathologists, all holding substantive NHS positions / 24-48 hours turnaround / Competitive flat fee structure for up to 7 specimens** (including courier, special stains, immunocytochemistry and billing) / Second opinion from expert panel / **Reports delivered securely by email** and via SSL-encrypted website / **Frozen sections & MDM support** / Privileged access to **educational material**.

« I know that the cases I send to LDPath will be reported by genuine specialists who hold substantive NHS positions and are at the forefront of their sub-specialty. »  
**Dr Raj Mallipeddi, Consultant Dermatologist**  
 St Thomas' Hospital



#### Dr Florence Deroide, MD - Partner

Consultant Dermatopathologist and Head of the Cellular Pathology Department at the Royal Free Hospital. Trained in France (Paris Ouest, Angers), more than 13 years of experience, including 10 in the UK.

Florence co-organises the Anglo-French dermato-pathology meeting in London and is a reviewer for Journal of Plastic, Reconstructive & Aesthetic Surgery.

**BAD 93rd Annual Meeting**  
 (9th - 11th July)  
 Meet our team on **STAND 41**



#### Dr Alistair Robson BSc (Hons) - Partner FRCPath DipRCPath

Consultant Dermatopathologist for 12 years at the tertiary referral centre St John's Institute of Dermatology.

Speaker at international conferences in the US, Middle & Far East and member of the Unna Darier Dermatopathology Society.

Numerous research works presented in the last 12 months at top international forums, e.g. American Academy of Dermatopathology, British Society of Dermatopathology, World Lymphoma Congress in Berlin...

Join the 100+ clinicians already benefiting from our first class services

# PROGRAMME INDEX

	PAGE NUMBER
<b>MONDAY</b>	
Overview	15
Dermatopathology Self Assessment	16
Trainee pre-conference session	17
SAS Session	18
<b>TUESDAY</b>	
Overview	19
Clinico-pathological cases - Joint BAD / BSD	20 - 21
Plenary	21 - 22
British Society for Skin Care in Immunocompromised Individuals	23 - 24
British Teledermatology Society	25
British Society for Cutaneous Allergy	26 - 27
British Society for Paediatric Dermatology	28 - 30
Historical	31 - 32
British Society for Dermatopathology	33 - 35
<b>WEDNESDAY</b>	
Overview	37
Plenary	38
Understanding Pharma	39
Medical Dermatology Plenary Session	40
BAD and BDNG Joint Meeting	41
British Society for Dermatological Surgery	42 - 45
British Photodermatology Group	46 - 47
<b>THURSDAY</b>	
Overview	49
Professor's & Registrars' Forum	50 - 51
Focus Session	51
CPD Session	52
<b>Additional meetings</b>	<b>12</b>
<b>Bristol Cup posters</b>	<b>53 - 57</b>

# MONDAY 8TH JULY – OVERVIEW

Monday 8th July	08:00-08:15	08:15-08:30	08:30-08:45	08:45-09:00	09:00-09:15	09:15-09:30	09:30-09:45	09:45-10:00	10:00-10:15	10:15-10:30	10:30-10:45	10:45-11:00	11:00-11:15	11:15-11:30	11:30-11:45	11:45-12:00	12:00-12:15	12:15-12:30	12:30-12:45	12:45-13:00	13:00-13:15	13:15-13:30	13:30-13:45	13:45-14:00	14:00-14:15	14:15-14:30	14:30-14:45	14:45-15:00	15:00-15:15	15:15-15:30	15:30-15:45	15:45-16:00	16:00-16:15	16:15-16:30	16:30-16:45	16:45-17:00	17:00-17:15	17:15-17:30	17:30-17:45	17:45-18:00	18:00-18:15	18:15-18:30	18:30-18:45
Registration Foyer	Registration Open																																										
Hall 2	Exhibition Build Up 08:00 - 20:00																																										
Hall 1B	DermSchool																																										
Hall 1C	Trainee Pre-conference session																																										
Hall 2A	BDNG																																										
Hall 2B	Tea																																										
Hall 4A	Trainee Welcome Lunch																																										
Hall 4B	SAS Lunch																																										
Hall 5	SAS committee meeting																																										
Hall 6	Speaker Preview																																										
Hall 7	Speaker Technical Room																																										
Hall 11A & B	DermSchool practical																																										
Hall 11C	DS Lunch																																										
Hall 12	DS Tea																																										
	BAD Sessions	Special Interest Groups	Exhibition / Posters	BAD Committee	Focus Session	BDNG Sessions	Non-BAD Meetings	Seminars / Symposia	Delegate Information																																		

# MONDAY 8TH JULY – OVERVIEW



## MONDAY 8TH JULY – DERMATOPATHOLOGY SELF ASSESSMENT PROGRAMME

## MONDAY 8TH JULY – TRAINEE PROGRAMME

TIME	CODE	PROGRAMME	ROOM
<b>12:30 – 18:00</b>			<b>JURYS INN HOTEL</b>
		<b>DERMATOPATHOLOGY SELF ASSESSMENT</b>	
12:30		Registration at ACC Liverpool (2 minute walk from Jurys Inn Hotel)	
12:45		Lunch	
13:30		Presentation of cases 1 - 20	
15:30		Tea and Coffee and further opportunity to register	
16:00		Presentation of cases 21 - 40	
18:00		End of session	

TIME	CODE	PROGRAMME	ROOM
<b>12:55 – 18:30 TRAINEE PRE-CONFERENCE SESSION</b>			<b>HALL 1C</b>
12:15 – 12:55		<b>Welcome Lunch</b>	Hall 3B
12:55		<b>Introduction</b> Dr Shaheen Haque-Hussain and Dr David de Berker	
13:00	TPC01	<b>Photodermatology</b> Dr Tsui Ling	
13:40	TPC02	<b>Biologics in psoriasis</b> Prof Catherine Smith	
14:20	TPC03	<b>Connective tissue disease</b> Dr Simon Megitt	
15:00	TPC04	<b>Lasers</b> Dr Vishal Madan	
15:40	TPC05	<b>Update on trainee issues</b> Dr Shaheen Haque-Hussain	
15:45		Tea / Coffee	Hall 3B
16:00	TPC06	<b>Ehlers-Danlos syndrome</b> Dr Nigel Burrows	
16:40	TPC07	<b>Psychodermatology</b> Dr Tony Bewley	
17:20	TPC08	<b>How to write a business case?</b> Tania von Hospenthal	
18:00	TPC09	<b>Quiz</b> Dr David de Berker	
18:20	TPC10	<b>Final remarks</b> Dr Shaheen Haque-Hussain and Dr David de Berker	
18:30		Close	
18:45 – 23:00		<b>Trainee &amp; DermSchool evening event</b>	Blue Bar

Approved by Royal College of Pathologists for CPD centre purposes to a maximum of 4 credits

Speakers: Eduardo Calonje  
Richard Carr  
Rino Cerio  
Martin Cook  
Paul Craig  
Sara Edward  
Lynne Jamieson  
Wolter Mooi  
Ed Rytina  
Maureen Walsh

# MONDAY 8TH JULY – SAS PROGRAMME

**TIME CODE PROGRAMME ROOM**

**12:15 – 17:35 SPECIALITY AND ASSOCIATE SPECIALISTS SESSION HALL 4A**

12.15 - 13.00	Registration and lunch	Hall 4B
13.00	<b>Welcome and Introduction</b> Dr Glenda Hill	
	CHAIR: Dr Inma Marie-Sole	
13.05	SAS01 <b>Occupational dermatitis and the role of patch testing</b> Dr Mark Wilkinson	
13.45	SAS02 <b>Difficult and unusual vilval conditions – how I manage them</b> Prof Hazel Bell and Mr John Kirwan	
14.25	SAS03 <b>Using immunoglobulin therapies in dermatology</b> Prof Carrock Sewell	
15.05	Tea / Coffee	Hall 4B
15.35	SAS04 <b>Systemic treatment for severe adult atopic dermatitis</b> Prof Nick Reynolds	
16.15	SAS05 <b>Cutaneous drug reactions – a brief overview and an update on identification of culprit drugs</b> Dr Michael Ardern-Jones	
16.55	SAS06 <b>Amyloidosis – an overview and guidance for dermatologists on when referral for further investigation is appropriate</b> Dr Ashutosh Wechalekar	
17.35	Closing remarks	
19.30 – 22.00	<b>SAS evening event</b>	Gusto Restaurant

# TUESDAY 9TH JULY – OVERVIEW

Time	08:00 - 09:00	09:00 - 10:00	10:00 - 11:00	11:00 - 12:00	12:00 - 13:00	13:00 - 14:00	14:00 - 15:00	15:00 - 16:00	16:00 - 17:00	17:00 - 18:00	18:00 - 19:00
Hall 1A	BSD & Clinicopath Cases	BSD & Clinicopath Cases	BSD & Clinicopath Cases	BSD & Clinicopath Cases	BSD Guest Lecture	BSD Guest Lecture	Scientific Session	Scientific Session	Scientific Sessions	Guest Lecture	Welcome Reception
Registration Foyer											
Hall 2											
Hall 1B											
Hall 1C	BSCA AGM	BSCA AGM	BSCA AGM	British Society of Cutaneous Allergy	BDNG AGM	BDNG LFS	BDNG AGM	BDNG AGM	BSD	BSD	
Hall 3A				Historical Symposium							
Hall 3B				British Society for Skin Care in Immunosuppressed Individuals							
Hall 4A				BSSCII AGM							
Hall 4B				British Teledermatology Society							
Hall 5											
Hall 6											
Hall 7											
Hall 8											
Hall 9											
Hall 11A & B											
Hall 11C											
Hall 12											
Hall 13											
Hall 14											
	BAD Sessions	Special Interest Groups	BDNG Sessions	Exhibition / Posters	BAD Committee	Focus Session	Non-BAD Meetings	Satellite Symposia	Delegate Information		



# TUESDAY 9TH JULY – DETAILED PROGRAMME

TIME	CODE	PROGRAMME	ROOM
08:00 – 18:00		Registration desk open	Galleria
09:15 – 12:35		BRITISH SOCIETY FOR CUTANEOUS ALLERGY (PAGE 26 – 27)	HALL 1C
09:00 – 12:30		BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY (PAGE 28 – 30)	HALL 11A & B
09:00 – 11:40		BRITISH SOCIETY FOR SKIN CARE IN IMMUNOCOMPROMISED INDIVIDUALS (PAGE 23 – 24)	HALL 3B
10:00 – 11:50		BRITISH TELEDERMATOLOGY SOCIETY (PAGE 25)	HALL 4B
09:30 – 10:26		<b>CLINICOPATHOLOGICAL CASES</b> Joint meeting with the British Society of Dermatopathology  CHAIRS: Dr Eduardo Calonje and Dr Paul Craig	Hall 1A
09:30	CPC-1	<b>Cutaneous cytomegalovirus infection in a patient with generalized pustular psoriasis: a case report</b> R. Green, F. Ali, E. McMullen, M. Judge and L. Motta	
09:37	CPC-2	<b>Trichodysplasia spinulosa</b> E. Rashidghamat, E. Calonje, Anissa Moktefi, Laurence Brudy and Agnès Carlotti	
09:44	CPC-3	<b>Cutaneous Epstein-Barr virus-associated smooth muscle tumours in the immunosuppressed</b> R.N. Matin, P. Harden, J.C. Bowling and K. Hollowood	
09:51	CPC-4	<b>Expanding the spectrum of Proteus syndrome: bilateral cerebriform plantar collagenomas and varicose veins secondary to a mosaic AKT1 mutation</b> J. Wee, P.S. Mortimer, M. Lindhurst, L. Biesecker and C.A. Holden	
09:58	CPC-5	<b>Disseminated malignancy in a patient with Gorlin syndrome: a rare case of metastatic basal cell carcinoma</b> S. Felton, R. Green, Lynne Jamieson and J.T. Lear	
10:05	CPC-6	<b>An evolving birth mark: bilateral segmental neurofibromatosis</b> F. Worsnop, S. Mansour and J. Natkunarajah	
10:12	CPC-7	<b>A mild form of Herlitz junctional epidermolysis bullosa with recurrent digital necrosis</b> M. Khan, F. Browne, P. Dopping-Hepenstal, L. Ozoemena, J.A. McGrath and C. Moss	
10:19	CPC-8	<b>Generalized eruptive keratoacanthoma of Grzybowski</b> C. Haddadeen, K. Hussein, E. Calonje and S. August	
10:26 – 11:14		Coffee & Exhibition	Hall 2
11:00 – 12:30		HISTORICAL COLLECTION SYMPOSIUM (PAGE 31 – 32)	HALL 3A
11:14 – 12:45		<b>CLINICOPATHOLOGICAL CASES CONTINUED...</b>  CHAIRS: Dr Lynne Jamieson and Dr Maureen Walsh	Hall 1A
11:14	CPC-9	<b>A case of acantholytic dermatosis localized to the male genitalia</b> M-C. Wilmoł, C. Perrett, J. Calonje, J. Weir and C. Bunker	

11:21	CPC-10	<b>Reversal of canities in an elderly white woman</b> A. Ranasinghe, E. Rytina and T.K.K. Ha	
11:28	CPC-11	<b>Perineural invasion in primary and recurrent cutaneous squamous cell carcinoma presenting as cranial nerve palsies and pain</b> P. Pratsou, W. Szczecinska, J.R. Marsden and I. Ahmed	
11:35	CPC-12	<b>Paraneoplastic palmar fasciitis and polyarthritis syndrome</b> S. Ong and H. Malhomme	
11:42	CPC-13	<b>Anti-small ubiquitin-like modifier activating enzyme positive dermatomyositis</b> Z. Laftah, E. Benton, B. Martin and R.W. Groves	
11:49	CPC-14	<b>Oral bisphosphonate in the treatment of synovitis, acne, pustulosis, hyperostosis and osteitis syndrome</b> F. Worsnop, B. Ho and J. Natkunarajah	
11:56	CPC-15	<b>AGEP / TEN overlap syndrome: A reaction not to be underestimated</b> F. Worsnop, L. Ostlere and J. Natkunarajah	

12:15  
Joint BAD/BSA Neil Smith Lecture  
**Lentiginous melanoma: emerging entity or misnomer?**  
Professor Wolter Mooi (Amsterdam, The Netherlands)

The literature on lentiginous melanoma will be critically reviewed, with an emphasis on terminology, diagnostic criteria and follow-up data. Reported data and my personal experience with these lesions appears to be more in line with a slowly evolving melanoma precursor than a full-fledged melanoma



12:45 – 14:30		Lunch & Exhibition	Hall 2
15:00 – 18:00		BRITISH SOCIETY FOR DERMATOPATHOLOGY (PAGE 33 – 35)	HALL 1C
14:15 – 18:00		<b>SCIENTIFIC SESSION - SUBMITTED PAPERS</b>  CHAIRS: Prof Christopher Bunker and Prof Malcolm Rustin	Hall 1A
14:15		Official Opening & Welcome – Prof Christopher Bunker	
14:30		<b>A tour of the new BAD Dermatology Smartphone App for medical students</b> Dr Ingrid Helbling and Dr James Coleman	
14:45	O-1	<b>Somatic mosaicism for activating mutations in codon 61 of NRAS is responsible for multiple congenital melanocytic naevi and neurocutaneous melanosis, and underpins the increased risk of melanoma</b> V. Kinsler, A. Thomas, M. Ishida, N. Bulstrode, P. Stanier, E. Healy, N. Sebire and G. Moore	
15:00	O-2	<b>Clinical characteristics and outcome in multibacillary leprosy patients treated with 12 months World Health Organization multidrug therapy multibacillary regimen: a retrospective analysis of 730 patients from India</b> S. Dogra, S. Kumaran and T. Narang	
15:15	O-3	<b>Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma</b> J.T. Lear, M. Gore, T. Guerrero-Urbano, R. Herd, R. Plummer, N. Basset-Seguín, J. Hansson, L. Mitchell, M. Starnawski, A. Hauschild1 and K Fife	

15:30 GL01 Guest Lecture – Introduced by Prof Malcolm Rustin Hall 1A



**Translating scleroderma – pathogenesis to targeted therapy**  
Professor Christopher Denton (London, UK)

Scleroderma (also termed systemic sclerosis) has the highest mortality of any autoimmune rheumatic disease with more than half of diagnosed patients ultimately dying as a direct result of the disease. However outcomes and survival have improved over the past decade due to systemic investigation, better therapies for organ-based complications. There are now licensed therapies for pulmonary hypertension and digital ulcer disease and an emerging evidence base supporting use of immunosuppression for skin and lung fibrosis. At the same time there is improved understanding of the nature of the pathology, if not its triggering or initiating factors. This lecture will review recent clinical progress in scleroderma, consider how the hallmark pathological processes might be targeted therapeutically. Pathogenesis involves interplay of vascular, immunological and fibrotic pathologies. Growing understanding of the similarities with other autoimmune diseases as well as better definition of the pivotal mediators or cell types that are important in connective tissue repair and fibrosis is providing impetus for more targeted approaches to treatment being developed. In addition, treatments that have been shown to be effective for other medical conditions such as gastro-oesophageal reflux or pulmonary arterial hypertension are being adapted and used in scleroderma. Thus, a pattern of translation of therapies within the clinical arena is emerging that complements the application of growing understanding of the disease biology that may facilitate new treatment targets or modalities. Finally, there are emerging data suggesting that intensive immunosuppression with autologous stem cell rescue might offer a durable treatment effect albeit with substantial treatment-related mortality. Whether more targeted or specific strategies targeting key pathways or mediators could achieve similar benefit with less toxicity will be considered in this presentation. There has been real progress in a “hard” disease and more can be expected if ongoing clinical trials fulfil their potential.

16:00 – 16:30 Tea and Exhibition Hall 2

16:30 O-4 **Mathematical modelling of patient flow through secondary care treatments for psoriasis: a novel approach to assist improvement to a complex healthcare system**  
K. Putman, V. Knight, P. Harper and A.V. Anstey

16:45 O-5 **The role of pharmacists in the management of dermatological conditions in the community: a survey of pharmacists in an urban area**  
C. Reid and T. Markham

17:00 O-6 **What should general practice trainees learn about childhood atopic eczema? A modified Delphi study exploring the views of healthcare professionals and parents of children with atopic eczema**  
D. Munidasa, T. McPherson and S.M. Burge

17:15 O-7 **‘Choose and Book’ teledermatology, a service overview**  
P. Bogucki and C. Charman

17:30 GL02 Guest Lecture – Introduced by Prof Christopher Bunker Hall 1A



**Health Education England - the new structure for education and training in the NHS**  
Professor Wendy Reid (London, UK)

18:00 Meeting close

18:00 - 19:30 Welcome Reception Galleria

## TUESDAY 9TH JULY – BRITISH SOCIETY FOR SKIN CARE IN IMMUNOCOMPROMISED INDIVIDUALS


TIME	CODE	PROGRAMME	ROOM
09:00 – 11:40		<b>BRITISH SOCIETY FOR SKIN CARE IN IMMUNOCOMPROMISED INDIVIDUALS</b>	<b>HALL 3B</b>
		CHAIRS: Dr Catherine Harwood and Dr Bill Phillips	
09:00		Welcome & Introduction by Prof Charlotte Proby	
09:05	BI05	<b>Developing a standardised actinic keratosis assessment protocol</b> <u>R.N. Matin</u> , P. Gaunt, D.L. McCartney, F. Ismail, S.J. Bowden, J.M. McGregor, J. Lear, C.M. Proby and C.A. Harwood	
09:15	BI02	<b>Response rates of different clinical subtypes of chronic mucocutaneous graft versus host disease to extracorporeal photopheresis</b> <u>S. Aguilar-Duran</u> , F. Dignan, S. Mahil, C. Wlodek, S. Saglam and F. Child	
09:25	BI03	<b>Prospective study of the incidence of skin cancer in prevalent renal transplant patients</b> <u>L. Mackintosh</u> and C. Geddes	
09:35	BI04	<b>Prevalence and associated risk factors for actinic keratoses and actinic field change among renal transplant patients</b> <u>S. Wallingford</u> , C. Proby, A. Vail, S. Russell, J. Lear and A. Green	
09:45	BI01	<b>Male genital dermatoses in immunocompromised patients</b> <u>T.N. Shim</u> , D. Hawkins, A. Muneer, S. Minhas, A. Freeman, C. Jameson, N. Francis, M. Dinneen and C.B. Bunker	
09:55	BI06	<b>Impact of skin cancers and premalignancies on the quality of life of organ transplant recipients</b> <u>L. Mitchell</u> , A. Gulati, J.M. McGregor, C.M. Proby, C.A. Harwood	
10:05		<b>Guest Lecture</b> <b>HIV Dermatology in the era of ARV</b> Prof Christopher Bunker (London, UK)	
10:40		Coffee Break and Poster Viewing	Hall 2
11:10		<b>Interactive Case Discussion with Expert panel</b> Dr John Lear, Dr Nilesh Morar and Dr Helen Ramsay	
11:10	BI09	<b>Fatal ecthyma gangrenosum associated with a psoas abscess in an immunosuppressed patient</b> <u>F. Worsnop</u> and J. Natkunarajah	
11:15	BI08	<b>Ecthyma gangrenosum caused by <i>Sphingomonas paucimobilis</i> secondarily infecting herpes zoster in an immunocompromised patient</b> <u>S.Z. Jaulim</u> , P. Gazzani, C. Kasparis, A. Bedlow and Jonathan Carter	
11:20	BI07	<b>Too much hair, not enough hair and acne after a kidney transplant: it's not always the drugs</b> <u>R. Atkar</u> , A. Rosenthal and C.A. Harwood	
11:25	BI10	<b>A rare case of diffuse cutaneous leishmaniasis in an immunocompromised patient on methotrexate</b> <u>K. Ngan</u> , G. Sharpe, T. O'Dempsey and N. Khirwadkar	
11:30	BI11	<b>Bullous pemphigoid mimicking toxic epidermal necrolysis in a HIV infected woman</b> U. Eke, <u>A. Eastaugh</u> , F. Nyatsanza, D. Lewis, M. Boothby, S.-L. Chua and R. Rajaratnam	



11:35	BI15	<b>Chronic herpes simplex infection in immunocompromised individuals, a diagnostic dilemma</b> M. Paul, J. Hague, S. Orpin and H. Al-Rawi
11:40		AGM
12:10		Meeting Close
<b>POSTERS</b>	BI12	<b>The stubborn skin nodules of <i>Mycobacterium chelonae</i></b> S. Tso, H. Recica, J. Brockley and J. Berth-Jones
	BI13	<b>Pattern of mucocutaneous manifestations in adult patients of leukaemia: cross-sectional prevalence study in 193 adult patients with leukaemia from a tertiary care centre in India</b> S. Dogra, S. Agrawal, P. Malhotra and U. N. Saikia
	BI14	<b>Evaluation of a nurse-led clinic for skin cancer awareness and surveillance of organ transplant recipients</b> L. Mitchell, A. Gulati, J.M. McGregor, C.M. Proby and C.A. Harwood
	BI16	<b>Hairy cell leukaemia presenting as cutaneous interstitial granulomatous dermatitis</b> N. Anjum, L.H. Lee, G. Soosaipillai, D. McCormick and B. Hughes
	BI17	<b>Haematological disorders and cutaneous malignancy: do they go hand in hand?</b> C. Wootton, A. Patel and P. Lawton
	BI18	<b>An unusual black nodule in a renal transplant recipient</b> J. Fleming, S. Howell, A. Robson, E. Calonje, J. Pattison, N. Attard and M. Wain
	BI19	<b>Nonmelanoma skin cancer in HIV positive patients</b> M. Rajpopat, A. Sahota and S. Rajpopat
	BI20	<b><i>Mycobacterium chelonae</i> infection in an immunosuppressed patient presenting in an isolated upper extremity sporotrichoid distribution: a challenging diagnosis!</b> F. Latheef and M. Shah
	BI21	<b>'A Dermatology Smear Campaign'</b> A. Devine, P. Yesudian and K.S. Chen
	BI22	<b>Patients presenting to Dermatology with an AIDS-defining illness - a report of three cases</b> V. Scott-Lang, M. Darling, S.A. Holme, M. Rahilly and S. Allan
	BI23	<b>Multi-drug resistant <i>Mycobacterium marinum</i> infection in an immunocompromised patient</b> P. Gazzani, S. Z. Jaulim, C. Kasparis, T. Gee and J. Carter
	BI24	<b>TB or not TB? Pre-biologic screening in a low-medium prevalence population</b> S. George, C. DeGiovanni, K. Ibrahim, C. Giles, P. Cadogan, E. Alexander and S. Doffman
	BI25	<b>A case of male breast cancer in a renal transplant recipient</b> J. Kluk and F. Ismail
	BI27	<b>Flexural psoriasis triggered by natalizumab for the treatment of multiple sclerosis: a very rare but reported association</b> F. Latheef and B.P. Walker
	BI28	<b>An unusual complication of systemic therapy in a patient with atopic eczema</b> S. Ogden and E. Stewart
	BI29	<b>Is skin biopsy needed in cases of high clinical suspicion of cutaneous graft-versus-host-disease?</b> V. Rajkomar, N. Aldoori and D.J. Gawkrödger
	BI30	<b>Calciophylaxis in a patient after 16 years of renal transplant</b> M. Fadhil and S. Shah

## TUESDAY 9TH JULY – BRITISH TELEDERMATOLOGY SOCIETY

TIME	CODE	PROGRAMME	ROOM
10:00 – 11:50		BRITISH TELEDERMATOLOGY SOCIETY	HALL 4B
10:00		<b>Welcome Introduction</b> Dr Saul Halpern	
10:10		<b>Guest Lecture</b> <b>Change in costs and efficiency after a decade of teledermatology; results based on 90,000 teleconsultations</b> Dr Job van der Heijden (Manager Research and Development, KSYOS Telemedical Centre, Amsterdam)	
		Teledermatology has been successfully implemented in The Netherlands resulting in improved care trajectories and lower associated costs:  2,816 general practitioners and 203 dermatologists performed teledermatology. 79,361 teleconsultations performed from 2006 to 2012 were included. In the group of patients where the general practitioner sent a teleconsultation to prevent a referral, 73% of physical referrals was prevented. In the group of patients where the general practitioner sent a teleconsultation for a second opinion, 15% were physically referred after teleconsultation. Conventional Care constituted 192,00 per dermatology patient. TeleDermatology constituted 68,00 per teleconsultation. Average price of patient that has been selected for TD: 157,06. The estimated cost reduction was 18%.  What were the factors leading to this success and are they generalizable to other countries, e.g. the UK.	
10:30	BT01	<b>Quality measures in a teledermatology service</b> T. Wing and D.A.R. de Berker	
10:50	BT02	<b>Teledermatology service in Tayside, Scotland: a snapshot</b> Y.N. Lau and C.J. Fleming	
11:10	BT03	<b>A new model of teledermoscopy combining service and education</b> E.V. Wray, B. Brant, F. Hussain and F.M. Muller	
11:30	BT04	<b>Mobile medical technology software applications for dermatologists and their patients</b> T. Lewis	
11:50		AGM	



# TUESDAY 9TH JULY – BRITISH SOCIETY FOR CUTANEOUS ALLERGY

TIME	CODE	PROGRAMME	ROOM
------	------	-----------	------

08:45 – 09:15		AGM	Hall 1C
---------------	--	-----	---------

<b>09:15 – 12:35</b>		<b>BRITISH SOCIETY FOR CUTANEOUS ALLERGY</b>	<b>HALL 1C</b>
----------------------	--	--	----------------

CHAIRS: Dr Helen Horne and Dr David Orton

- |       |      |  |        |
|-------|------|--|--------|
| 09:15 |      | <b>Prosser - White Oration</b><br><b>Allergic Contact Dermatitis to isothiazolinones - the emerging story</b><br>Prof Jeanne Duus Johansen (Gentofte Hospital, Denmark)  |        |
| 09:45 | CD01 | <b>Methylchloroisothiazolinone and methylisothiazolinone contact allergy: a new epidemic</b><br><u>R. Urwin</u> and S.M. Wilkinson   |        |
| 09:55 | CD02 | <b>Outbreak of contact allergy to cosmetic preservative: history repeats itself (again)</b><br><u>J. Mann</u> , I. White, J. White, P. Banerjee and J. McFadden  |        |
| 10:05 | CD03 | <b>Occupational disease in beauticians reported to The Health and Occupation Research network from 1996 to 2011</b><br><u>C. Kwok</u> , A. Money, M. Carder, S. Turner, R. Agius, D. Orton and S.M. Wilkinson  |        |
| 10:15 | CD04 | <b>Our experience with alitretinoin in the management of patients with chronic, severe hand eczema</b><br><u>J. Dua</u> , N. Gallacher, K. Warburton and S. Cooper   |        |
| 10:25 | CD05 | <b>An ethnographic insight into the psychological impact of hand eczema</b><br><u>A. Bewley</u> , N. Mason, J. Rawlins and S. Walker   |        |
| 10:35 |      | Coffee Break   | Hall 2 |
|       |      | CHAIRS: Dr Sarah Wakelin and Dr Mark Wilkinson   |        |
| 11:05 |      | <b>Guest Lecture</b><br><b>Update on Fragrance Allergy</b><br>Dr Deirdre Buckley (Bath, UK)  |        |
| 11:25 | CD06 | <b>Patch testing to the 26 individual labelled fragrances over a two-year period</b><br><u>J. Mann</u> , J. McFadden, J. White, I. White and P. Banerjee   |        |
| 11:35 | CD07 | <b>Prevalence of allergy to oxidized limonene and linalool in the U.K.</b><br><u>H. Audrain</u> , C. Kenward, C.R. Lovell, C. Green, A.D. Ormerod, J. Sansom, M.M.U. Chowdhury, S.M. Cooper, G. Johnston, S.M. Wilkinson, C.M. King, N. Stone, H.L. Horne, C. Holden, B. Statham, J. Williams, S. Wakelin, J. English and D.A. Buckley |        |
| 11:45 | CD08 | <b>An outbreak of allergic contact dermatitis to citral in beauticians working in a health spa</b><br><u>P. De Mozzi</u> and G.A. Johnston   |        |
| 11:55 | CD09 | <b>A multicentre review of bakery and dental series allergens tested for cheilitis in the U.K.</b><br><u>S. Fatah</u> , H.L. Horne, S.M. Wilkinson, D.J. Gawkrödger, J. English, C.M. Green, A.D. Ormerod, M.M.U. Chowdhury, S.M. Cooper, N.M. Stone, C.M. King and G. Johnston  |        |

- |                |      |  |  |
|----------------|------|--|--|
| 12:05          | CD10 | <b>Denture stomatitis resulting from tertiary butylhydroquinone- and methylhydroquinone- induced allergic contact mucositis</b><br><u>N.Y.Z. Chiang</u> and D.A. Thompson  |  |
| 12:15          | CD11 | <b>A case of wheat protein isolate allergy manifesting as anaphylaxis and cosmetic allergy</b><br><u>A. Lloyd-Lavery</u> , S.M. Cooper, G. Ogg and J. Reed   |  |
| 12:25          | CD12 | <b>Metal allergy and joint replacement: advice in the absence of guidelines</b><br><u>D.J. Gawkrödger</u>  |  |
| <b>POSTERS</b> | CD13 | <b>Allergy at arm's length: occupational contact dermatitis to carbimazole.</b><br><u>N. Farquharson</u> and I. Coulson  |  |
|                | CD14 | <b>Wound dressings: a potential source of acrylate induced allergic contact dermatitis</b><br><u>N.Y.Z. Chiang</u> and D.A. Thompson   |  |
|                | CD15 | <b>A case of systemic contact dermatitis due to intra-articular injection of Depo-Medrone (methylprednisolone)</b><br><u>Y. Robson</u> , M. Hughes and N. Stone  |  |
|                | CD16 | <b>Sensitivity to p-phenylenediamine (PPD): positive relationship of response to PPD on patch testing and cross-reactions with other chemically related allergens</b><br><u>B. Thomas</u> , I. White, J. White, J. McFadden and P. Banerjee  |  |
|                | CD17 | <b>Audit to assess whether a history of a cosmetic reaction or allergic contact reactions to fragrance mix 1 might be predictive of allergic contact reactions to oxidized linalool 6% and oxidized limonene 3%.</b><br><u>C. Holden</u> , T. AlEnezi, A. Sultan and D.J. Gawkrödger |  |

# TUESDAY 9TH JULY – BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY

**TIME CODE PROGRAMME ROOM**

**09:00 – 12:30 BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY HALL 11A & B**

CHAIRS: Dr Olivia Schofield and Dr Hossain Shahidullah

- 09:00 PA01 **Early-onset eczema and disease severity are the main risk factors for food sensitization at 3 months of age in exclusively breastfed infants**  
*D. Greenblatt, M. Perkin, K. Logan, T. Marrs, S. Radulovic, L.E. Campbell, S.F. MacCallum, W.H.I. McLean, G. Lack and C. Flohr*
- 09:10 PA02 **Oral azathioprine for the treatment of childhood eczema: safety profile and guidelines for monitoring**  
*N. Fuggle, W. Bragoli, A. Mahto, S. Syed, N. Roberts, A. Martinez, J.I. Harper, D. Lomas, M. Glover and V. Kinsler*
- 09:20 PA03 **Predictors of persistent meticillin-resistant Staphylococcal aureus colonization in paediatric atopic dermatitis**  
*C. Foley, R. Cunney, S. Gleeson, P. Lenane and B. O'Donnell*
- 09:30 PA04 **Risk factors for the onset and persistence of childhood eczema: birth cohort study**  
*M. Ridd, C. Penfold, R. Morris, S. Sullivan, M. Santer, A. Roberts, G. Dunnill, P. Magin, L. Paternoster and S. Purdy*
- 09:40 PA05 **Interleukin-10 receptor mutation presenting with severe nappy ulceration and infantile inflammatory bowel disease**  
*B.S. McDonald, S. Narayanan, M. Elawad and K. Batta*
- 09:46 PA06 **Problematic spitzoid lesions in childhood**  
*S. Mashayekhi, C. Flohr, A. Greig, M. Neat, G. Ferrara, O.E. Dadzie, K.M. Acland, C.M. Stefanato and A. Robson*

09:56 **Guest Lecture**  
**Next generation diagnostics for inherited skin disease**  
Prof John McGrath (London, UK)



Advances in DNA sequencing methods have changed how we diagnose genodermatoses in 2013. New techniques such as whole exome sequencing now permit screening of all the coding regions of the genome in one go to find pathogenic mutations. Moreover, sequencing platforms are becoming cheaper and quicker and more accessible to dermatologists. This lecture will provide examples of how next generation sequencing is being used to diagnose inherited skin diseases and how current generation clinicians can access and benefit from the new DNA sequencing technologies.

10:30 Coffee and posters Hall 2

CHAIRS: Dr Mary Glover and Dr Susannah Baron

- 11:00 PA07 **Efficacy of topical timolol 0.5% ophthalmic solution to treat infantile haemangioma: a study of 105 haemangiomas from a single centre**  
*D. Khanna and P. Chakravarty*
- 11:10 PA08 **An audit of the initiation of oral propranolol to treat infantile haemangioma in 35 patients**  
*N. Farquharson, P. Arkwright and T. Clayton*

- 11:20 PA09 **Unusual granulomatous skin manifestations in children with primary immunodeficiency**  
*S. Verykiou, A. Taylor and S. Leech*
- 11:26 PA10 **Rituximab in childhood pemphigus: an experience of five patients**  
*A.J. Kanwar and K. Vinay*
- 11:36 PA11 **A review of the treatment and demographics of children in the U.K. with vitiligo**  
*A. Scott, N. Dinani and N. Roberts*
- 11:46 PA12 **Localized epidermolytic ichthyosis secondary to a novel keratin 1 mutation occurring in monozygotic twins and treated with acitretin**  
*J. Wee, A. Terron-Kwiatkowski, D. Baty, E. O'Toole and J. Natkunarajah*
- 11:52 PA13 **Are we harming our children on long-term prescribed oral medications from the effects of sugar and other excipients? A case of tooth decay and review of current guidance**  
*E. Burden-Teh, G. Kemsley and J.C. Ravenscroft*

12:00 **Guest Lecture**  
**The Inherited Photodermatoses in children: a whistlestop tour of pathogenesis, genetics and management**  
Dr Robert Sarkany (London, UK)



The inherited photodermatoses are a relatively rare but severe and potentially dangerous group of diseases which generally present to Paediatric Dermatologists. They classify into one group of diseases due to hereditary metabolic defects, and another group due to defects in DNA repair. This lecture will focus mostly on the Childhood Porphyrias and on Xeroderma Pigmentosum. The commonest childhood porphyrias are Erythropoietic Protoporphyrria, Congenital Erythropoietic Porphyria (Gunter's Disease) and Variegate Porphyria. In addition to the complex issues around photoprotection against visible light and treatment of photosensitivity, the lecture will tackle the lessons from the pathogenesis and genetics, and the management of systemic and internal complications of the childhood porphyrias. Xeroderma pigmentosum is a rare autosomal recessive multisystem disorder which poses unique challenges for clinical management. Early diagnosis and absolute photoprotection against UV currently are the only ways of reducing morbidity and prolonging lifespan, but both pose challenges for Clinicians and patients alike. The lecture will cover these issues as well as potential new treatments and diagnostic methods.

12:30 Close

- POSTERS**
- PA14 **Two cases of rapidly involuting congenital haemangioma**  
*W. Szczecinska and H. Shahidullah*
  - PA15 **LEOPARD syndrome or Noonan syndrome? A difficult distinction in early childhood**  
*S. Madhogaria, S. Sharif and C. Moss*
  - PA16 **Vascular Ehlers–Danlos syndrome presenting with abnormal recurrent bruising in a 3-year-old girl**  
*J. Newsham, G.J. Sobey and T.H. Clayton*
  - PA17 **A difficult case of atopic eczema: useful learning points**  
*M.S. Shareef, L. Albenali, M.J. Cork and S.M. Clark*
  - PA18 **Cutaneous xanthomas in homozygous familial hypercholesterolaemia: an important lesson**  
*N.Y.Z. Chiang, C. Agwu, S. Vijay, P. Abdullah and M. Maheshwari*



- PA20 **A tale of two brothers: neonatal lupus in an antibody-negative family**  
A. Khoo and E.P. Burova
- PA21 **Ichthyosis prematurity syndrome in two siblings**  
N. Farquharson, S. Sivashankar and I.H. Coulson
- PA22 **Deep infantile haemangioma responding to propranolol after the proliferative stage**  
E. Burden-Teh and R. Murphy
- PA23 **Lichen planopilaris: the paradoxical role of tumour necrosis factor antagonists**  
M. Walsh, P. Jayasekera and R.A.G. Parslew
- PA24 **Phenotypic and genotypic overlap between acro-dermato-ungual-lacrima-tooth syndrome and ectrodactyly-ectodermal dysplasia-clefting syndrome: a better classification is needed**  
S. Madhogaria, L. Ozoemena, J.A. McGrath and C. Moss
- PA25 **Aleukaemic congenital leukaemia cutis**  
S. Ayob, J. Payne, M. Al-Adnani and S. Garg
- PA26 **Aneurysmal fibrous histiocytoma in a 3-year-old child**  
A. Ranasinghe, L. Hook, E. Rytina, I. Grant, C. Fischer and J. Gass
- PA27 **Dermatitis simulata and the art student**  
H. Bridgestock and H. Recica
- PA28 **Poikiloderma of Clericuzio**  
A. Kapadia, M.S. Shareef and S.M. Clark
- PA29 **Buschke-Ollendorff syndrome affecting lower-limb function in two children**  
C. Goodhead, C. Blasdale and A. Taylor
- PA30 **Beckwith-Wiedemann syndrome with multifocal infantile haemangiomas and hepatic haemangioendotheliomas**  
L. Craven and A. Belgi
- PA31 **A case of juvenile xanthogranuloma with bilateral retinal detachment**  
C. Kwok, A. Kapadia, W. Merchant and S.M. Clark
- PA32 **Orofacial granulomatosis predating the onset of multiple autoimmune diseases: an autoimmune association?**  
N.Y.Z. Chiang and A. Abdullah
- PA33 **Localized congenital giant juvenile xanthogranulomas resolving with atrophic sequelae**  
S. Sanyal, K. Batta and A. Rubin
- PA34 **Spinal dysraphism and its cutaneous signs**  
M. Paul, A. Loffeld, H. Goodyear and D. Rodrigues
- PA35 **A case of congenital tufted angioma: a rare vascular tumour**  
S. Rajan and C. Kennedy

## TUESDAY 9TH JULY – HISTORICAL

TIME	CODE	PROGRAMME	ROOM
11:00 – 12:30		HISTORICAL SYMPOSIUM	HALL 3A

CHAIRS: Dr Nick Levell

- 11:00 H01 **Thomas Bateman through the looking glass: a newly discovered personal archive of a sensitive man**  
L. Millard
- 11:15 H02 **Dermatology back in the day: a review of inpatient care in the 1940s**  
V. Scott-Lang, E.T. Ooi and C. Benton
- 11:30 H03 **The life and times of the mighty mite**  
K.E. Davies and P.D. Yesudian

- 11:45 H04 **The story of Daniel Carrion: a fatal quest for insight into oroya fever and verruga disease**  
E. McNulty-Brown and A.V. Anstey

- 12:00 **Guest Lecture**  
**King George III's madness; the porphyria myth**  
Prof Timothy Peters (Birmingham, UK)



King George III (1738-1820) had, 4 possibly 5 episodes of 'madness', diagnosed as manic-depressive psychosis. In 1965 Ida Macalpine and her son Richard Hunter, rejected this diagnosis and claimed that George had recurrent attacks of acute porphyria. In spite of well-founded criticisms, Macalpine and Hunter were able to gather extensive and lasting support for their claims.

Recent re-evaluation of the King's medical records has shown that Macalpine & Hunter were highly selective in their reporting omitting any evidence that did not support a diagnosis of porphyria, and indicates that the King suffered from recurrent attacks of acute mania, i.e., bipolar disorder.

The reasons for and consequences of Hunter and Macalpine's misleading claim will be discussed.

- POSTERS H05 **How the rain forests saved our skin!**  
P.D. Yesudian, P. Balasubramaniam and R.K. Lister
- H06 **H. Radcliffe Crocker: doyen of British dermatology**  
L.L. Griffin and C.E.M. Griffiths
- H07 **Joseph Goldberger and the enigma that was pellagra**  
E.D. Owen, Y. Robson and A.V. Anstey
- H08 **Why Pthirus pubis don't watch Sex and the City**  
K.S. Chen and P.D. Yesudian
- H09 **Hans Reiter: his syndrome and shameful past**  
K. Salako and M. Kalavala
- H10 **Sir Jonathan Hutchinson: freckles and foibles**  
C. Wootton
- H11 **The Scottish Women's Hospital and increased survival from gas gangrene in World War I**  
V. Scott-Lang, G. Kavanagh and D. Fisher

- H12 **Arthur Whitfield, 1868–1947: much more than an ointment**  
A. Sharma, W. Malein and S. Orpin
- H13 **‘Wigging out!’**  
A. Devine and P.D. Yesudian
- H14 **The men behind the lines**  
F. Worsnop, B. Ho and J. Natkunarajah
- H15 **Historical use of radiation epilation for tinea capitis in childhood: a life sentence?**  
K. Ngan, P. Jayasekera, R.M. Azurdia and J. Verbov
- H16 **The mystery of the Black Sore (Kara Yara)**  
M. Malik and P.D. Yesudian
- H17 **Francis Xavier Dercum, 1856–1931: a less than dolorous life**  
M. Crow, A.H.M. Heagerty and S. Orpin
- H18 **On target: erythema multiforme, a history**  
Z. Venables and N.J. Levell
- H19 **Gerhard Henrik Armauer Hansen (1841–1912), the man who unveiled the mystery of leprosy**  
M. Paul, Y. Mansouri and A. Loffeld
- H20 **What’s in a name? The historical descriptions of hidradenitis suppurativa**  
R. Coelho and N.J. Levell
- H21 **New empires and old enemies: the story of tuberculosis and its cutaneous manifestations**  
S. Laird, P. Gazzani and C. Kasparis

## TUESDAY 9TH JULY – BRITISH SOCIETY FOR DERMATOPATHOLOGY

TIME	CODE	PROGRAMME	ROOM
08:00 – 09:00		Executive BSD Committee Meeting	Hall 14
09:30 – 12:15		Clinicopathological Cases, Joint meeting with the British Association of Dermatologists	Hall 1A
12:15 – 12:45		Joint BAD/BSD Neil Smith Lecture <b>Lentiginous melanoma: emerging entity or misnomer?</b> Prof Wolter Mooi (Amsterdam, The Netherlands)	Hall 1A
14.30 – 15.00		BSD AGM	Hall 1C
<b>15:00 – 18:00 BRITISH SOCIETY FOR DERMATOPATHOLOGY</b>			<b>HALL 1C</b>
		CHAIRS: Dr Eduardo Calonje and Dr Lynn Jamieson	
15:00		Introduction and comment on posters	
15:05	DP01	<b>Merkel cell carcinoma in the U.K.: an urgent need for evidence-based management</b> M. Sommerlad, C.A. Harwood and R. Cerio	
15:12	DP02	<b>A 10-year retrospective review of vulval squamous cell carcinoma associated with lichen sclerosis</b> S.H. Hussain, M. Chattopadhyay, A. Shiraz, G. Meligonis, P. Baldwin and J. Sterling	
15:19	DP03	<b>Is granuloma faciale part of the IgG4-related disease spectrum?</b> E. Ieremia, Agnes Carlotti and E. Calonje	
15:26	DP04	<b>p63 and nuclear factor- B expression in primary cutaneous B-cell lymphoma: further evidence for pathogenetic heterogeneity</b> Z. Shukur, P. Coates, A. Subtil, W. Kempf, D. Sahni and A. Robson	
15:33	DP05	<b>Retrospective 20-year review of pathology reporting of eccrine porocarcinoma in a U.K. dermatology unit</b> A.S.W. Yong, K.Y.C. Lee, L. Igali, I. Nunney, S.N. Shah and E. Tan	
15:40	DP06	<b>A retrospective study of 13 cases of vulvar melanoma</b> M. Chattopadhyay, E. Rytina, G. Meligonis, P. Baldwin and P. Todd	
15:47	DP07	<b>Cutaneous granulomatous lesions in congenital immunodeficiency states</b> C. Fleming, B. Martin, E. Calonje and C. Smith	
15:54	DP08	<b>Perineural inflammation in scleroderma: systematic characterization of a poorly recognized but potentially useful histopathological feature</b> C.A. Dhaliwal, A.I. MacKenzie and A. Biswas	
16:01	DP09	<b>Report of two cases of the so-called ‘malignant’ dermatofibroma: can behaviour be predicted on morphology?</b> W. Rickaby, E. Ieremia, M. del Carmen Gonzalez Vela, J. Fernando Val-Bernal, G. Saldanha and E. Calonje	
16:08		Coffee break	Hall 2

16:30 CHAIRS: Dr Eduardo Calonje and Dr Paul Craig

16:30

**Early melanoma. Small melanoma. Naevoid melanoma. How many are melanomas?**

Prof Wolter Mooi (Amsterdam, The Netherlands)



Neoplastic transformation and progression to malignancy is a multistep process, but diagnostic tumor pathology strives to categorize individual lesions as either benign or malignant. Only tumors that never behave as cancer are called benign.

The problem of this oversimplification is, that groups of lesions that only rarely behave as cancers, need to be labelled as malignant, for truly benign lesions never do. Benignity guarantees no further trouble, malignancy indicates a chance of further trouble, even when that chance is small.

When a very thin melanocytic lesion is diagnosed as melanoma, everyone expects the patient to do well, and no one challenges the pathologist's diagnosis if the patient does well. However, the situation is entirely different if the pathologist has diagnosed a benign entity, but the lesion subsequently behaves as a cancer. Accordingly, there is a constant pressure on diagnostic pathologists to call a "difficult" lesion malignant.

Obviously, one cannot diagnose naevus when in doubt about the possibility of a malignant potential of a lesion. In order to avoid overdiagnosing melanoma on the one hand, and taking risks on the other, I believe it is wise to use a category of melanocytic tumours (or proliferations) of uncertain malignant potential (MELTUMPs).

17:15 DP10 **Clinicopathological analysis of 54 patients with cicatricial alopecia**

A. Khalid, K.S. Chen and P.D. Yesudian

17:22 DP11 **Cryoglobulinaemia: the tip of the rete ridge**

K. Muttardi, E. Calonje and B. DeSilva

17:29 DP12 **Bullous scabies associated with positive direct immunofluorescence**

B.S. McDonald, C. Orteu and V. Swale

17:36 DP13 **An unusual case of finger ulceration**

N. Bansal, A. Imtiaz, S. Taibjee, R. Carr and H. Kutzner

17:43 DP14 **Squamous cell carcinoma arising within disseminated superficial actinic porokeratosis**

M. Chattopadhyay, E. Rytina and P.M. Todd

17:50 DP15 **The forgotten sign: half-half blisters as a presentation of meticillin-resistant Staphylococcus aureus bullous impetigo in a 20-year-old woman returning from the tropics**

J. Dua, A. Gafita, E. Davies, C. Rodriguez-Garcia and S. Grabczynska

17:57 Best presentation prize and close

**POSTERS** DP16 **Lymphoplasmacytic plaque in children: a report of two adult cases**

E.T. Ooi, A. Biswas, O. Schofield, V.R. Doherty and C.S. Murray

DP17 **To compare bacillary index on slit-skin smear with bacillary index of granuloma in patients with leprosy: its relevance to present therapeutic regimens**

M.S. Kumaran, S. Dogra, T. Narang and U.N. Saikia

DP18 **A review of melanoma pathology reporting: looking beyond just Breslow thickness**

S. Cheung, L. Ahmed and A. Youssef

DP19 **Chronic fibrosing vasculitis of the penis**

S. Nasir, C. Murray, V. Swale, E. Calonje and S. Mazzon

DP20 **A rare variant of fibrosarcomatous dermatofibrosarcoma protuberans**

P. Fiandero, A. D'Souza, E. Calonje and S. Hoque

DP21 **Infliximab-induced alopecia: a recently documented antitumour necrosis factor- adverse event and a novel cause of noncicatricial alopecia**

E. Ieremia, K. Anneke and C. Stefanato

DP22 **Mid-dermal elastolysis of the back presenting 6 years post-toxic epidermal necrolysis**

C. Cunningham, L. Joseph and J. Ferguson

DP23 **A rare presentation of cutaneous pseudolymphoma as a preleukaemic state**

M. Sivaramakrishnan, R. Kerr, A. Evans and A. Affleck

DP24 **Lisinopril-induced pemphigus**

C. Haddadeen, L. Craven, W. Chong and C. Stephens

DP25 **Think zinc: acquired acrodermatitis enteropathica in a patient with metastatic adenocarcinoma of unknown primary**

V. Salter, S. Ekanayake, M. Malik and M. Petkar

DP26 **Cutaneous perineural granulomatous inflammation masquerading as leprosy**

B. Shaheen, P. Woo and A. Barbieri

DP27 **A widespread granulomatous eruption heralding the onset of myelodysplastic syndrome**

A. Fogo, H. Hunter, D. McLornan and S. Walsh

DP28 **Multiple scrotal verruciform xanthomas in a West African man**

D. O'Callaghan, V. Dvorakova, P. Marren and P. Regan





Kilimanjaro Challenge

London 2 Brighton Challenge

London Marathon

# Leading the fight against SKIN DISEASE

Trans Pennine Challenge

Moonriders Cycle Ride

British 10K

Ride London 100

Great North Run

## Find out how you can help

The British Skin Foundation  
 4 Fitzroy Square, London W1T 5HQ  
[www.britishskinfoundation.org.uk](http://www.britishskinfoundation.org.uk)

For general enquiries and to make a donation:  
 0207 391 6341  
[admin@britishskinfoundation.org.uk](mailto:admin@britishskinfoundation.org.uk)

For fundraising and events enquiries:  
 0207 391 6088  
[events@britishskinfoundation.org.uk](mailto:events@britishskinfoundation.org.uk)

For press and media enquiries:  
 0207 391 6347  
[press@britishskinfoundation.org.uk](mailto:press@britishskinfoundation.org.uk)

## WEDNESDAY 10TH JULY – OVERVIEW

	08:00 - 09:00	09:00 - 10:00	10:00 - 11:00	11:00 - 12:00	12:00 - 13:00	13:00 - 14:00	14:00 - 15:00	15:00 - 16:00	16:00 - 17:00	17:00 - 18:00	18:00 - 19:00	19:00 - 20:00
Wednesday 10th July	Submitted papers	Guest Lecture	Understanding Pharma	Annual General Meeting	Registration Open	Registration Open	Med Derm Session	Med Derm Session	Med Derm Session	Med Derm Session	Med Derm Session	Med Derm Session
Hall 1A	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer	Registration Foyer
Hall 2	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters	Exhibition & Posters
Hall 1B	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal	BDNG - Medico Legal
Hall 1C	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods	BDNG - Interpreting Bloods
Hall 3A	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym	Almarril Sat Sym
Hall 3B	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym	Beleford Sat Sym
Hall 4A	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym	AbViv Sat Sym
Hall 4B	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym	Janssen Sat Sym
Hall 5	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub	for Wales Phototherapy Sub
Hall 6	BAD Officers	BAD Officers	BAD Officers	BAD Officers	BAD Officers	BAD Officers	BAD Officers	BAD Officers	BAD Officers	BAD Officers	BAD Officers	BAD Officers
Hall 7	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview	Speaker Preview
Hall 8	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub	Skin Cancer Prevention Sub
Hall 9	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting	BSMD Committee Meeting
Hall 11A & B	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection	BDNG - Sun Protection
Hall 11C	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog	BDNG - Legion Recog
Hall 12	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers	BDNG - Lasers
Hall 13	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting	UKDCTN AGM/Steering Group Meeting
Hall 14	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting	BDJ Editorial Board meeting
	BAD Sessions	Special Interest Groups	BDNG Sessions	Exhibition/Posters	BAD Committee	Focus Session	Non-BAD Meetings	Satellite Symposia	Delegate Information			



# WEDNESDAY JULY 10TH – DETAILED PROGRAMME

TIME	CODE	PROGRAMME	ROOM
08:00 – 18:00		Registration desk open	Galleria
08:00 – 08:45		<b>ALMIRALL SATELLITE SYMPOSIUM (PAGE 58)</b>	<b>HALL 3A</b>
08:00 – 08:45		<b>BEIERSDORF SATELLITE SYMPOSIUM (PAGE 58)</b>	<b>HALL 3B</b>

TIME	CODE	PROGRAMME	ROOM
08:30 - 09:45		<b>SCIENTIFIC SESSION - SUMMITTED PAPERS</b>	
		CHAIRS: Dr Jan McLelland and Dr David Eedy	
08:30	O-08	<b>Topical glycopyrrolate spray 2% reduces axillary hyperhidrosis to a similar extent as Botox injections</b> <u>D. Baker</u>	
08:45	O-09	<b>Diagnostic criteria for erosive lichen planus affecting the vulva: an electronic-Delphi consensus exercise</b> <u>R. Simpson, K. Thomas, P. Leighton and R. Murphy</u>	
09:00	O-10	<b>Use of electrochemotherapy in the management of unresectable malignant melanoma and metastatic skin deposits</b> <u>N. Clayton, A. Sadri, M. Boyce, V. Wolstenholme, C. Harwood, G. Moir, J. McGregor and R. Cerio</u>	
09:15	GL03	Guest Lecture – Introduced by Prof Malcolm Rustin	



### Inherited skin barrier defects in atopic eczema

Professor Irwin McLean (Dundee, UK)

Atopic dermatitis (“eczema”) is a common complex disease where a combination of strong genetic predisposing factors combine with appropriate environmental stimuli and lead to inflammatory skin disease. Ichthyosis vulgaris (common dry, flaky skin) is arguably the most common Mendelian single gene disorder, where about 1 in 90 of the British population have a severe form and as many as 1 in 7 have mild or sub-clinical form of the disease. In 2006, we identified the first mutations in the filaggrin gene as the cause of ichthyosis vulgaris and showed that the condition is semi-dominant – homozygotes are severely affected; heterozygotes are mildly affected (*Nature Genetics* 38:337-342 2006). Profilaggrin is the main protein component of keratohyalin granules in the epidermis and its processed product, filaggrin, is involved in biogenesis of and subsequent hydration of the stratum corneum (*J Cell Sci*, 122:1285-1294). The nonsense or frameshift mutations identified in the filaggrin gene lead to complete loss of profilaggrin/filaggrin protein production in the epidermis. Surprisingly, these mutations are very common in the population and are carried by 5-14% of people of white European ancestry. Since many individuals with ichthyosis vulgaris also have eczema and associated allergies, and the filaggrin gene is located within a known eczema susceptibility locus, we went on to investigate these mutations in atopic disease. This revealed that filaggrin loss-of-function mutations are a major risk factor for atopic eczema and associated allergic conditions, importantly including atopic asthma and allergic rhinitis (*Nature Genetics* 38:441-446, 2006; *Nature Genetics* 39:650-654, 2007). These studies have been very widely replicated, including in non-white populations. In light of recent genomewide association analysis, filaggrin is now recognised as the major gene for eczema. Currently, we are working to understand the gene-environment interaction that is clearly central to the pathogenesis of eczema, as well as developing new medicines aimed at improving skin barrier function in atopy.

09:45 - 10:40

### UNDERSTANDING PHARMA

Hall 1A

CHAIRS: Prof Christopher Bunker and Mr Howard May

09:45



### Skin health – beauty and well-being

Dr Michèle Verschoore, Medical Director, L’Oréal Research & Innovation

To the extent that they help improve our appearance, cosmetics can affect how we relate to ourselves and to others, and as such can improve quality of life. Such benefits may be objectively demonstrated using validated methods and quality-of-life scales.

The aim of this review will be to assess the effects of cosmetics on well-being in various situations based on studies using objective measurement methods. It can be demonstrated that in pathological settings, the use of cosmetics can significantly improve the quality of life and well-being of patients, resulting in better acceptance of their disease and better therapeutic compliance. The use of cosmetics has also been shown to exert positive effects on self-esteem and social relations. A growing body of studies demonstrates the beneficial effects of cosmetics on well-being under normal physiological conditions. We can conclude that today, the effects and benefits of cosmetics can be measured objectively using quality-of-life scales, allowing initiation of actions for the rediscovery of well-being and self-esteem.

### Basics of Dermatology Medicines Development

Dr Barbara White, SVP and Head of R&D, Stiefel

Learning Objectives:

1. Understand challenges in creating a significant value proposition for a new medicine in dermatology: creating value for patients, physicians, health agencies, and payers
2. Understand approaches to manage some common risks at different stages in development of medicines for dermatology, including some common challenges in topical formulations
3. Understanding the promise of translational medicine approaches in development of new medicines for dermatology

10:00



10:15



### Quo Vadis, global dermatology

Mr Humberto Antunes, President and CEO, Galderma S.A

The world is changing rapidly. Those interested in dermatology wonder how the world will look and how their practice of medicine will be in 10, 20 or 30 years. The gloomy scenarios from the year 2000 have not taken place for the specialist in dermatology in 2013. In this talk, we will discuss some of the projections for global dermatology and how industry, academia and physicians can work together to improve patient outcomes and to shape a prosperous future for the practice.

10:40 – 11:00

Coffee

Hall 2

11:00 – 13:00

Annual General Meeting (members only)

Hall 1A

13:00 – 14:30

Lunch & Exhibition

Hall 2

13:15 – 14:15	<b>MEDA SATELLITE SYMPOSIUM (PAGE 59)</b>	<b>HALL 11A &amp; B</b>
13:15 – 14:15	<b>ABBVIE SATELLITE SYMPOSIUM (PAGE 60)</b>	<b>HALL 3A</b>
13:15 – 14:15	<b>JANSSEN SATELLITE SYMPOSIUM (PAGE 59)</b>	<b>HALL 3B</b>
14:00 – 17:10	<b>BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY (PAGE 42 - 45)</b>	<b>HALL 1C</b>
14:30 – 17:45	<b>BRITISH PHOTODERMATOLOGY GROUP (PAGE 46-47)</b>	<b>HALL 12</b>

14:30 – 16:00		<b>SCIENTIFIC SESSION – MEDICAL DERMATOLOGY &amp; SUBMITTED PAPERS</b>	Hall 1A
	CHAIRS:	Dr Nick Levell and Dr Simon Meggitt	
14:30	MD01	<b>Advances in hidradenitis management</b> Prof Gregor Jemec (Copenhagen, Denmark)	
15:00	O-11	<b>Infliximab for hidradenitis suppurativa; should we be measuring antibody levels?</b> <u>Z. Laftah</u> , Z. Arkir, E. Agius and N. Desai	
15:15	O-12	<b>A novel use for botulinum toxin A in the management of ileostomy and urostomy leaks</b> <u>V. M. Smith</u> and C.C. Lyon	
15:30	MD02	<b>Mastocytosis management for the Dermatologist</b> Dr Clive Grattan (Norwich, UK)	
16:00 – 16:30		Tea & Exhibition	Hall 2
16:30 – 18:00		<b>Scientific Session – Medical Dermatology &amp; Submitted Papers Continued...</b>	Hall 1A
	CHAIRS:	Dr Sarah Walsh and Dr Michael Ardern-Jones	
16:30	MD03	<b>Systemic treatments for the photodermatoses</b> Dr Robert Sarkany (London, UK)	
		 <p>Systemic therapy is a mainstay of treatment for the photodermatoses for a variety of reasons. Firstly, some photodermatoses, including Porphyria Cutanea Tarda, Hydroa Vacciniforme and Lupus, are cutaneous manifestations of generalised and systemic diseases, requiring treatment of the underlying systemic disorder. Secondly, some of the Inflammatory Photodermatoses are severe and tend to require treatment with systemic immunosuppressant drugs, particularly severe Chronic Actinic Dermatitis and Actinic Prurigo. Thalidomide is the systemic immunosuppressant of choice in Actinic Prurigo. Finally, we routinely use oral Psoralens as an immunosuppressant activated by UVA, when we give PUVA.</p>	
17:00	MD04	<b>Future psoriasis therapy beyond TNF-a blockade</b> Prof Nick Reynolds (Newcastle, UK)	
		 <p>The introduction of biological therapies, primarily TNF inhibitors and ustekinumab, has been transformational for patients with resistant moderate-to-severe psoriasis who fulfill NICE eligibility criteria. However, patient surveys have shown high levels of dissatisfaction with current therapies, principally related to lack of efficacy and/ lack of robustness of response. Nevertheless, recent insights into disease pathogenesis, mechanisms of therapeutic action and of therapeutic failure are now realizing: a) new therapeutic agents such as anti-IL-17 antibodies and novel small molecule inhibitors, b) the potential for individualization of therapy and c) possibility of inducing remission and modifying the course of disease.</p> <p>However, the efficacy of therapeutic agents is variable and currently unpredictable with both primary and secondary failure (caused by lack/loss of efficacy and adverse events). There is strong patient support for personalizing therapies to individual patients. Recent insights offer the potential of developing tests that predict therapeutic outcomes for individual patients.</p>	
17:30	O13	<b>The risk of postoperative complications in patients with psoriasis or psoriatic arthritis on biological therapy</b> <u>W. Bakkour</u> , H. Pursell, H. Chinoy, C.E.M Griffiths and R.B Warren	
17:45	O-14	<b>Drug survival of fumaric acid esters for psoriasis: a retrospective study</b> <u>N. Ismail</u> , B. Kirby, P. Collins and A. Lally	

18:15 – 19:00	NOVARTIS SATELLITE SYMPOSIUM (PAGE 60)	HALL 3A
18:15 – 19:00	LEO PHARMA SATELLITE SYMPOSIUM (PAGE 61)	HALL 3B

14:45 – 16:45		<b>JOINT SESSION - BRITISH ASSOCIATION OF DERMATOLOGISTS AND BRITISH DERMATOLOGICAL NURSING GROUP</b>	Hall 11A & B
	CHAIRS:	Dr Ferina Ismail and Carrie Wingfield	
14:45	JM01	<b>Melanoma / targeted therapies</b> Dr Louise Fearfield	
15:05	JM02	<b>Skin Surgery: The Nurse Consultant's Perspective</b> Carrie Wingfield	
15:25	JM03	<b>Non melanoma skin cancer / pre-cancerous skin conditions</b> Dr John Lear	
15:45	JM04	<b>The development of BDNG Skin Cancer Nursing Competencies</b> Saskia Reeken	
16:05	JM05	<b>Skin cancer surgery / Mohs</b> Dr Ed Seaton	
16:25	JM06	<b>The Nursing Care of Patients on Systemic Medication for Malignant Melanoma</b> Rachel Duncan	
19:30 – 00:00		Annual Dinner	St George's Hall
19:30 – 23:00		BSDS Annual Dinner	The Athenaeum



# WEDNESDAY 10TH JULY – BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY

TIME	CODE	PROGRAMME	ROOM
14:00 – 17:10		BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY	HALL 1C

CHAIRS: Dr Graeme Stables and Dr Vindy Ghura

14:00	DS01	<b>Safety, complications and patients' acceptance of Mohs micrographic surgery under local anaesthesia: results from the U.K. Mohs Acceptance and Patient Safety Collaboration Group</b> <i>W.S. Hussain, A. Affleck, F. Al-Niaimi, A. Cooper, E. Craythorne, C. Fleming, V. Ghura, J. Langtry, C. Lawrence, S. Loghdey, R. Mallipeddi, L. Naysmith, T. Oliphant, R. Rahim, S. Rice, M. Sivaramkrishan, G. Stables, S. Varma</i>
14:07	DS02	Abstract withdrawn
14:14	DS03	<b>Surgical excision vs. imiquimod 5% cream for basal cell carcinoma: a multicentre noninferiority randomized controlled trial</b> <i>H. Williams, F. Bath-Hextall, M. Ozolins, G. Colver, W. Perkins, S. Armstrong and P. Miller</i>
14:21	DS04	<b>Short-duration cold trypsinization as a novel method in noncultured epidermal suspension transplantation in stable vitiligo</b> <i>A.P. Holla</i>
14:28	DS05	<b>Analysis of a dermatopathology audit of Mohs section reporting by Mohs surgeons in a Mohs fellowship training dermatology surgery unit</b> <i>S.A. Rice, T.J. Oliphant, R.R. Rahim, C.M. Lawrence and J.A.A. Langtry</i>
14:35	DS06	<b>Change in histological diagnosis following Mohs micrographic surgery</b> <i>S. Verykiou, T.J. Oliphant, R.R. Rahim, C.M. Lawrence and J.A.A. Langtry</i>
14:42	DS07	<b>Two-centre audit of Mohs surgery using a U.K. national Mohs minimal dataset: next steps to test the agreed minimum dataset</b> <i>M. Sivaramkrishnan, A. Affleck, A. Evans, L. Naysmith, L. Macfarlane and C.J. Fleming</i>
14:49	DS08	<b>Five-year experience of the Johnson square procedure for lentigo maligna and lentigo maligna melanoma: the Nottingham experience of 15 cases</b> <i>A. Patel, W. Perkins, I. Leach and S. Varma</i>
14:56	DS09	<b>Curettage: an economical use of everyone's time? A retrospective audit into the treatment of cutaneous squamous cell carcinoma in a U.K. district general hospital</b> <i>C. Mitchell, W.A. Woo, E. Wakefield and J. Hextall</i>
15:03	DS10	<b>Skin adhesive use in cutaneous surgery</b> <i>Y.N. Lau, W. Hussain, C.M. Green and A. Affleck</i>
15:10	DS11	<b>Suspension sutures to achieve aesthetically favourable horizontal primary closure of infraorbital Mohs defects to avoid ectropion: a case series of six patients</b> <i>V. Samarasinghe and R. Mallipeddi</i>

15:17 DS12 **The Z-plasty pedicle flap for enhanced cosmesis in upper cutaneous lip repair**  
*R. Urwin and W. Hussain*

15:24 DS13 **The 'apical lip flip' for challenging defects of the nasal ala**  
*R. Urwin and W. Hussain*

15:31 – 16:00 Coffee Break Hall 2

CHAIRS: Dr Raj Mallipeddi and Dr Colin Fleming

16:00



**Guest Lecture**  
**Dermatological Surgery; A view from the other side of the pond**  
*Prof Chris Zachary (Irvine, California, USA)*

25 years later, the transformation in British Dermatological Surgery is astounding. In 1987, there was a reluctance on the part of dermatologists in the UK to accept the concept that we should be performing anything but the most menial of surgical procedures. Those of us had surgery fellowship training in the US were considered odd ball, and somewhat inferior and certainly less significant than the 'complete dermatologist'. Thus started the slow transition, first in Mohs surgery and reconstruction, and then in laser and aesthetic medicine. There is an understanding in the US that dermatologists are more skilled and more economical than some of our other surgical specialists in the removal of skin cancers. And particularly in the field of lasers and devices, dermatological surgeons are preeminent in their development and utilization. This presentation will review some of the latest trends and surgical treatments for skin problems in the USA, and evaluate which side of the Pond is excelling in 2013!

16:45 DS14 **A prospective study of secondary intention scalp wound healing and outcomes following skin cancer excision**  
*S.A. Rice, T.J. Oliphant, C.M. Lawrence and J.A.A. Langtry*

16:52 DS15 **The lenticular island pedicle flap for large centrofacial defects**  
*M.S. Shareef and W. Hussain*

16:59 DS16 **The 'bridge rotation': a novel repair option for periocular and paranasal surgical defects**  
*R. Montgomery and W. Hussain*

17:10 – 17:45 BSDS AGM Hall 1C

**POSTERS** DS17 **Variations in histological subtypes of basal cell carcinoma between initial biopsy and final excision**  
*E. Storan, B. Moran and P. Ormond*

DS18 **Mohs micrographic surgery for desmoplastic trichoepithelioma: a report of 11 cases**  
*S.A. Rice, T.J. Oliphant, C.M. Lawrence and J.A.A. Langtry*

DS19 **'The spaghetti technique': a useful technique in the surgical management of lentigo maligna and lentigo maligna melanoma**  
*S. Sidhu, A. Morris, K. May and R. Motley*

DS20 **Pilot study of use of 'photographic rhinometry' following Mohs micrographic surgery for skin cancers**  
*S. Rajpara and C.J. Fleming*

DS21 **Potential use of patient-reported outcome measures after Mohs surgery**  
*M. Sivaramkrishnan, C.J. Fleming and A. Affleck*

- DS22 **The 'inverted' advancement and inferior rotation of the nasal sidewall flap for defects of the medial canthus**  
[R. Urwin](#) and [W. Hussain](#)
- DS23 **The specialist nonmelanoma skin cancer multidisciplinary team**  
[M.S. Shareef](#), [W. Hussain](#), [C. Fenn](#), [F. Roberts](#), [W. Merchant](#) and [G.I. Stables](#)
- DS24 **Management of Merkel cell carcinoma in the south east of England: a retrospective cohort analysis of 67 cases over a 7-year period**  
[G. Coltart](#), [J. Schofield](#) and [S. Coltart](#)
- DS25 **A prospective qualitative study of patient satisfaction following secondary intention wound healing**  
[S. Verykiou](#), [K. Aljefri](#), [T.J. Oliphant](#) and [J.A.A. Langtry](#)
- DS26 **Carcinoma cuniculatum on the heel treated pain free with Mohs micrographic surgery using ultrasound-guided sciatic nerve block**  
[A. Patel](#), [N. Bedford](#) and [S. Varma](#)
- DS27 **Trends in incidence of invasive cutaneous squamous cell carcinoma in the north of Scotland over the last 35 years: implications for healthcare spending and the need for increased local sun protection advice**  
[A. Bonsall](#), [E. Semple](#), [E. Hussain](#) and [S. Rajpara](#)
- DS28 **Improving cosmesis at the donor site using discarded skin following an interpolated paramedian forehead flap procedure**  
[M. Rajpopat](#) and [N. Sheth](#)
- DS29 **'Skimming the surface': a review of split-thickness skin grafting practice and preferences among dermatological surgeons in the U.K.**  
[M.S. Shareef](#) and [W. Hussain](#)
- DS30 **The contralateral subgaleal advancement-rotation flap for the single-stage repair of large defects of the lateral forehead and temple**  
[M.S. Shareef](#) and [W. Hussain](#)
- DS31 **The 'shark-fin' flap for medium-to-large-sized defects of the preauricular cheek**  
[R. Montgomery](#) and [W. Hussain](#)
- DS32 **Hidradenitis suppurativa: the surgical option**  
[J. Sullivan](#), [N. Kelemen](#) and [S. Al-Ghazal](#)
- DS33 **Cutaneous odontogenous sinus tracts: a clinician's dilemma**  
[M.S. Kumaran](#), [T. Narang](#), [S. Dogra](#) and [S. Bhandari](#)
- DS34 **Destructive treatment of lymphangiomas with carbon dioxide laser and diathermy**  
[C. Duhovic](#), [J. Soo](#), [N. Kuganenderan](#), [P. Mortimer](#) and [C.C. Harland](#)
- DS35 **Immobilization of full-thickness skin grafts using a multilayered polyurethane foam dressing**  
[W.L. Ho](#), [K.E. Eustace](#), [P. Ormond](#) and [R. Barry](#)
- DS36 **Double hatchet flap for reconstruction of lower-limb defects: technique and comparison with type II keystone flap**  
[F. Hussain](#) and [F. Muller](#)

- DS37 **The merits of using alternate staining with toluidine blue and haematoxylin and eosin during Mohs micrographic surgery for basal cell carcinomas**  
[N. Anjum](#), [P. Shepherd](#) and [G. Segal-Hall](#)
- DS38 **Self-funding low-priority benign skin lesion surgery: an evaluation of a new service**  
[S. Anthony](#), [F. Tatnall](#), [K. Batta](#) and [K. Mead](#)
- DS39 **Disparity in skin surgery patient information leaflets: do we need a national template?**  
[W. Hunt](#) and [E. McGrath](#)
- DS40 **Trilobed flap repair for nasal tip and alar defects in eight patients**  
[R.R. Rahim](#) and [J.A.A. Langtry](#)
- DS41 **Use of the Skin Cancer Index to identify preoperative psychological morbidity**  
[A. Affleck](#), [M. Moyes](#) and [C.J. Fleming](#)
- DS42 **Laser resurfacing of facial hypertrophic scarring with an erbium: YAG laser**  
[D. Seukeran](#)
- DS43 **An extremely delayed reaction following an intradermal filler: a case highlighting the need for tighter regulation and a U.K. register of adverse events related to minimally invasive cosmetic procedures**  
[W. Bakkour](#) and [T. Griffiths](#)

# WEDNESDAY 10TH JULY – BRITISH PHOTODERMATOLOGY GROUP

TIME	CODE	PROGRAMME	ROOM
14:30 – 17:45		BRITISH PHOTODERMATOLOGY GROUP	HALL 12

CHAIRS: Dr Robert Sarkany and Dr Christopher Edwards

## BPG 2013 GUEST SPEAKERS

14:30



### Modern Photopatch Testing: A product of co-operation between photo and contact dermatology groups

Prof James Ferguson (Dundee, UK)

Photocontact dermatitis is a recognised clinical problem which started with the sulphonamides, salicylanilides and antibacterial agents, the. Phototoxicity due to topical agents is well described as the phytophotodermatitis group due mainly to psoralen chemical and UVA exposure. Photoallergy, as investigated by photopatch testing has a history going back many years. Unfortunately it has long been recognised to be bedevilled by lack of a standardised technique. To a certain extent it has fallen between two subspeciality stools.

This problem needing a solution was recognised jointly by the European Photodermatology Group and the European Society for Contact Dermatitis. Some 13 years ago a joint task force was established by these Groups, Over the following decade a series of “interested expert” workshops produced consensus views of photopatch test methodology, essentially a movement to sort out the chaos of multiple methodologies, variable irradiation techniques and large unwieldy lists of photoallergens complicated by largely obsolete chemicals. The UK took on the lead role and has encouraged the new consensus methodology established by workshops with initially a UK and Dutch study which has been followed by Pan European work with a consensus modernised group of photopatch test chemicals, namely around the sunscreens and topical nonsteroidal anti-inflammatory agents. The appropriate use of this test system, as with photopatch testing, reveals the diagnosis in patients with an unexplained photoexposed site dermatitis.

This joint activity has popularised a standardised methodology throughout Europe. It is expected that patients will now also benefit from a commercially available adapted standard European photopatch test list of agents. It is an agreed view that photoallergy is an underdiagnosed skin condition.

15:05

### The Photobiology of Vitamin D

Prof Antony Young (London, UK)

CHAIRS: Dr Robert Dawe and Dr Victoria Goulden

15:40

PD01

### Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions

M. Sethi, A. Lehmann, A. Robson, D. McGibbon, R. Sarkany and H. Fassihi

15:55

PD11

### MMP12 is induced by UVA1 but not UVB

A. Tewari, K. Gryz, R. Sarkany and A. Young

16:10

PD03

### Self-administration of hospital-based narrowband UVB (TL-01) phototherapy: a feasibility study in an outpatient setting

S. Yule, S. Sanyal, S. Ibbotson, H. Moseley and R.S. Dawe

16:25

Coffee Break

Hall 2

17:00

PD04

### Evaluation of patient’s and healthcare professional’s knowledge and views about home phototherapy.

S. Lumley, K. Salako and Alex Anstey

17:15

PD05

### A regional audit of phototherapy services

R. Urwin, D. Turner and V. Goulden

17:30

PD06

### An overview of patients investigated in the National Photodiagnostic Service in a tertiary setting over a 22-year period

H. Naasan, R.S. Dawe, H. Moseley and S. Ibbotson

17:45

Close of meeting

17:45 – 18:15

BPG AGM

Hall 12

## POSTERS

PD07

### Determination of optimum operating point for hand held minimum erythema dose device

D. Turner and V. Goulden

PD08

### Subcutaneous panniculitis-like cutaneous T-cell lymphoma treated with UVA-1 phototherapy

V. M. Smith, R. Rose and V. Goulden

PD09

### An illustrative case series of X-linked dominant protoporphyria

M. Seager, S. Whatley, A.V. Anstey and T. Millard

PD10

### Do display monitors and ‘tablet’ screens emit sufficient UVA or UVB to affect photosensitive patients?

A. Patel, E. Burden-Teh, M. Lam, P. Akram, R. Farley and S. Varma

PD12

### 2011–2012 Audit and survey of phototherapy services in the West Midlands (UK)

J. Powell and M. Kaur





# THURSDAY 11TH JULY – DETAILED PROGRAMME

TIME	CODE	PROGRAMME	ROOM
08:00 – 18:00		Registration desk open	Galleria
08:30 – 12:15		<b>PROFESSORS &amp; REGISTRARS FORUM</b>	Hall 1A
08:30 – 10:25	CHAIRS:	Prof Eugene Healy and Prof Nick Reynolds	
08:30	RF01	<b>High-sensitivity C-reactive protein as a marker of psoriasis severity and cardiovascular risk</b> C. Reid, C. Sweeney, A-M. Tobin and B. Kirby	
08:45	RF02	<b>Hypertension is prevalent in psoriasis and should be treated more aggressively</b> M. Carroll, A-M. Tobin and B. Kirby	
09:00	PR01	<b>Psoriasis: a multi-system disorder</b> Prof Brian Kirby (Dublin)	
09:20	RF03	<b>A controlled trial of mindfulness-based stress reduction in psoriasis and investigation of telomerase as a biomarker of psychological distress</b> K. Adamzik, G. O'Malley, C. Sweeney, M. Keane, A. Lally, A-M. Tobin, P. D'Alton and B. Kirby	
09:35	RF04	<b>Vemurafenib, photosensitivity and human papillomavirus infection: an emerging story</b> M. Sommerlad, K. Purdie, H. Rizvi, J. McGregor, P. Szlosarek, V. Wolstenholme, R. Cerio and C. Harwood	
09:50	PR02	<b>Influence of sunlight exposure on vitamin D status in the UK</b> Prof Lesley Rhodes (Manchester)	
10:10	RF05	<b>Gamma-secretase mutations in hidradenitis suppurativa (acne inversa): a new insight into disease pathogenesis</b> A. Pink, M. Simpson, N. Desai, D. Dafou, P.S. Mortimer, C.H. Smith, R. Trembath and J.N.W.N. Barker	
10:25 – 11:10		Coffee & Exhibition	Hall 2
		<b>PROFESSORS &amp; REGISTRARS FORUM CONTINUED...</b>	
11:10 – 12:15	CHAIRS:	Prof Christopher Bunker and Prof Malcolm Rustin	
11:10	RF06	<b>Cutaneous features of dermatomyositis associated with myositis specific antibodies</b> M.-L. Daly, P. Gordon and J.D. Creamer	
11:25	PR03	<b>Melanoma therapy: The elusive magic bullet</b> Prof Frank Nestle (London)	
11:45	RF07	<b>Filaggrin-null individuals with and without eczema have a higher proportion of CD11c positive antigen presenting cells than wild type individuals</b> Z.C.I. Venables, C.S. Leitch, N.P. Madarasingha, P.M. Fitch, S.E. Howie, J. Schwarze and R.B. Weller	

12:00 RF08 **Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population**  
S.M. Langan, L. Smeeth, D.J. Margolis and S.L. Thomas

12:15 GL04 **Arthur Rook Oration**  
Guest Lecture – Introduced by Professor Christopher Bunker Hall 1A



**Understanding skin disease through the perspective of innate immunity**  
Professor Richard Gallo (San Diego, USA)

The skin protects itself with barriers to the environment and by detecting danger from the environment. Antimicrobial peptides are a critical element of the defensive barrier, while a variety of pattern recognition receptors such as the Toll-like receptors (TLRs) are key to detecting injury. This presentation will describe these findings and discuss their relevance for clinical dermatology.

13:00 – 14:30 Lunch & Exhibition Hall 2

## 13:15 – 14:00 FOCUS SESSION: CLINICAL SERVICES HALL 1C

The Clinical Services Focus session will be hosted by Dr Graham Sharpe, Clinical Vice President and Tania von Hospenthal, Clinical Services Manager with guest speaker Roy Lilley, an established, independent health policy analyst, writer, broadcaster and commentator on health and social issues.

The session will focus on the new commissioning landscape and the many facets of service design, to assist members with meeting these challenges. Commissioning of dermatology services seems increasingly complicated within the new NHS structure, particularly with CCGs stepping into the role of commissioner for acute and community dermatology services. We will outline important aspects to help departments deal with commissioning and improve their own service provision, presenting some of the resources which are currently being developed by the CSU for members.

The CSU would like to draw up a Commissioning FAQ ahead of the session targeting members keys concerns. In order to do this, we be contacting members attending the focus session, in advance of the day.

## 13:15 – 14:00 FOCUS SESSION: DERMOSCOPY HALL 3A

Speakers: Dr Jonathan Bowling and Dr Andrew Affleck  
Content: In this 45 minute action packed focus session the speakers will cover:

- Novel dermoscopic features of melanoma in situ
- Tropical dermoscopy - the merits of ex-vivo dermoscopy
- Results of the UK dermoscopy survey
- Dermoscopic pitfalls and pearls

## 13:15 – 14:00 FOCUS SESSION: GENITAL DERMATOLOGY HALL 11A & B

13:15 **What are the BSSVD and the BSMGD?**  
Dr Jennifer Yell and Dr William Porter

13:25 **The importance of pathology in the diagnosis of genital dermatology**  
Dr Luisa Motta, Consultant Dermatopathologist, Salford

13:40 **How best to treat "pelvic" pain**  
Dr Winston F de Mello, Consultant in Pain Medicine, Manchester

13:55 Final minutes: Any questions?

14:30 - 18:00 CONTINUING PROFESSIONAL DEVELOPMENT SESSION Hall 1A

CHAIRS: Dr Graham Sharpe and Dr Richard Parslew

- 14:30 CPD01 **What's New in Infectious Diseases**  
Dr Mahreen Ameen (London)
- 15:00 CPD02 **What's New in Contact Dermatitis**  
Dr Mark Wilkinson (Leeds)
- 15:30 GL05 Guest Lecture – Introduced by Prof Christopher Bunker



**A Current Therapeutic Armamentarium for Chronic Idiopathic and Autoimmune Urticaria/Angioedema**  
Professor Nicholas A. Soter (New York, USA)

H1-type antihistamines are the therapy of choice in the management of patients with chronic idiopathic or autoimmune urticaria/angioedema. For patients who have failed to benefit from antihistamines, alternative therapeutic measures may be considered. In double-blind trials, the addition of leukotriene receptor inhibitors, nifedipine, dapson, or dipyridamole to antihistamines achieved beneficial responses. Colchicine, hydroxychloroquine, cyclosporine mycophenolate mofetil, tacrolimus, methotrexate, high-dose intravenous immunoglobulin, plasmapheresis, and narrow-band ultraviolet B phototherapy have been of benefit in clinical trials. Biologic agents were successfully used anecdotally in a few patients. Thus, additional levels of therapeutic agents are available for the treatment of refractory disease.

16:00 – 16:30 Coffee Break Upper Level

- 16:30 CPD03 **Trends in Dermatological Surgery**  
Dr Raj Mallipeddi (London)
- 17:00 CPD04 **What's new in General Medicine for Dermatologists**  
Dr Catherine Orteu (London)
- 17:30 **President's Address**  
Professor Christopher Bunker
- 17:45 Close of meeting

## POSTERS

The posters are situated within the Exhibition Hall and there will be a dedicated poster viewing hour on **Tuesday July 9th from 13:00 – 14:00**. All presenting authors have been asked to stand by their poster at this time. There will also be an e-poster display area within the Exhibition Hall.

## BRISTOL CUP POSTERS

### Clinicopathological Cases

- P01 A case of diffuse dermal angiomatosis related to a breast implant**  
C. Kwok, M. Shareef, S. Edward and M. Wilkinson
- P02 Metastatic basal cell carcinoma**  
N. Salmon, L.A. Fearfield, M. Gore and J. Larkin
- P03 Animal-type melanoma: how should we manage this rare entity?**  
C. Sinclair, S. Allan, I. Nawroz and S. Fraser
- P04 Three generations of hereditary leiomyomatosis associated with renal cell cancer**  
Z. Venables, A. Ramaiya, S. Holden and G.W.M. Millington
- P05 Dermatoses localizing to radiotherapy sites**  
R. Hellen, C. Kiely, A. Murad, P. Lenane, F.J. Moloney and N. Mulligan
- P06 Churg–Strauss presenting with urticated skin lesions**  
N. Salmon and L.A. Fearfield
- P07 Female-pattern hair loss in a hypopituitarism: possible response to androgen replacement therapy**  
A. Jamil and A. Messenger
- P08 Dössekker tuberous myxoedema revisited: a rare variant of scleromyxoedema**  
F.R. Ali, P. Ho, I.H. Chaudhry, L. Motta and R.J.G. Chalmers
- P09 Urticarial vasculitis associated with an acquired reactive perforating collagenosis in pregnancy**  
F. Worsnop, S. Eriyagama, J. Wee, B. Ho and J. Natkunarajah
- P10 de Toni–Fanconi syndrome secondary to fumaric acid esters**  
C. Reid, J. Holian, D. Kane and B. Kirby
- P11 First case report of localized bullous pemphigoid occurring on an oedematous leg secondary to chronic superficial femoral artery occlusion**  
J. Dua, E. Davies, A. Gafita, C. Rodriguez-Garcia and S.A. Grabczynska
- P12 The psychological impact of a diagnosis of basal cell carcinoma**  
S. Noel, D. Dunn and R. Wilson
- P13 Toxic epidermal necrolysis-like lupus**  
N. Spierings, L. Ffolkes and V. Akhras
- P14 Erythema multiforme caused by ingestion of atropine eye drops: a previously unreported phenomenon**  
F. Latheef, R. El-Naes and R.M. Strauss
- P15 Primary cutaneous cryptococcosis in a patient with chronic lymphocytic leukaemia treated with alemtuzumab**  
E. Storan, W. Ho, M. McMenamin and B. Wynne
- P16 Biological switching: infliximab- and adalimumab-induced folliculitis**  
F. Worsnop, K. Misch and J. Natkunarajah
- P17 Flucloxacillin-induced unusual drug reaction in a child: an example of epitope spread**  
M. Chattopadhyay, S. Haque-Hussain, E. Rytina and T.K.K. Ha
- P18 Leukaemia cutis mimicking pyoderma gangrenosum**  
Y. Mansouri, T.T. Lew and J.M.R. Goulding



- P19 Atypical hidradenitis suppurativa involving nonflexural body sites**  
A. Affleck and H. Nassan
- P20 Multiple exquisitely painful leg ulcerations in a teenager**  
J. Brockley, H. Recica, S. Tso and A. Ilchyshyn
- P21 Lupus erythematosus and inclusion body myositis: an important association**  
R. Green, L. Motta, R.G. Cooper and R.B. Warren
- P22 Papuloerythroderma of Ofuji: case report and review of the literature**  
Y. Mansouri, B. Stranks, P. Colloby, E. Todd and M.R. Kaur
- P23 Novel mutation in keratin 10 causing autosomal dominant epidermolytic ichthyosis**  
R. Lamb, A. Terron-Kwiatkowski, J. Lang, I. McLean and M. Zamiri
- P24 Langerhans cell histiocytosis: treatment of cutaneous disease with azathioprine**  
A. Rao and A. Chu
- P25 Multiple halo naevi associated with tocilizumab treatment**  
K.H. Kuet and M.J.D. Goodfield
- P26 Acute necrotizing eosinophilic myocarditis: a rare complication of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms syndrome. A case report**  
C. Mitchell, W.A. Woo and J. Hextall
- P27 Identification of a novel mutation causing Bloom Syndrome with no facial telangiectasia or erythema**  
J. Powell, N. Cooper and F. Browne
- P28 Vemurafenib-exacerbated eruptive disseminated syringomas**  
C. Haddadeen, C. Morgan, K. Hussein, R. Osborne and A. Belgi
- P29 Autonomic leuconychia**  
L. Newell and D.A.R. de Berker
- P30 X-linked recessive dyskeratosis congenita: an important dermatological diagnosis**  
J. Powell, C. Moss, I. Dokal, R. Carr, S. Taibjee and B. Cave
- P31 Clouston syndrome caused by a heterozygous mutation in connexin 30, resembling pachyonychia congenita**  
G. Hale, N. Wilson, F. Smith and M. Zamiri
- P32 Multicentric reticulohistiocytosis treated with adalimumab**  
S. Verma, N. Ralph and P. Collins

### Education, Training, Service, Audit

- P33 An audit of acute dermatology referrals at a district general hospital**  
B. Shaheen and C. Soon
- P34 Dermatology on-call service: is it really necessary?**  
N. Anjum, L.H. Lee, A. Haworth and B. Hughes
- P35 The U.K. Dermatology Clinical Trials Network Trainee Group: developing evidence-based practice and research engagement among dermatology trainees**  
R.N. Matin, J.M. Batchelor, C. Flohr, A.E. Macbeth, E. Smith, C. Layfield, J.R. Ingram and H.C. Williams
- P36 Is dermatology a forgotten subject within core medical training?**  
N. Harper, S. Hamer and J. Bong
- P37 An audit to support the need for emergency dermatology training**  
V. Pinder, F. Worsnop, J. Wee and L. Ostlere
- P38 Addressing a lack of dressings knowledge**  
C. Wootton and P. Whitehead

- P39 The 5-year itch: comparison of walk-in vs. choose-and-book emergency dermatology clinics in 2007 and 2012**  
N. Spierings, F. Worsnop, R.A. Marsden and V. Akhras
- P40 Dermatology training in the U.K.: does it reflect the diversity of our population?**  
A. Salam and O.E. Dadzie

### General Dermatology

- P41 Infections in the ustekinumab psoriasis clinical trial programme: final report with up to 5 years of follow-up**  
B. Strober, P.D. Ghislain, M. Lebwohl and P. Szapary
- P42 Utility of a national hair microscopy service**  
J. Nesbitt and D.A.R. de Berker
- P43 The revised Leeds acne grading scale: how accurate and clinically useful is it?**  
F. Latheef, A. Eady, R. El-Naes and A. Layton
- P44 Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms**  
T.T. Lew, D. Creamer and S. Walsh
- P45 Malignancies in the ustekinumab psoriasis clinical development programme: final report with up to 5 years of follow-up**  
K. Papp, K. Gordon, V. Ho and P. Szapary
- P46 Psychological impact of delusional infestation: preliminary results**  
R. Shah and A.P. Bewley
- P47 Practical experience of biological treatment of very severe psoriasis: a retrospective case-cohort study of patients with a baseline Psoriasis Area Severity Index score greater than 20**  
N. Ponnambath, M. Kalavala, A.V. Anstey, V. Piguet and J.R. Ingram
- P48 One person's pink is another person's purple**  
R. Ellis, D. Chew and N. Rajan
- P49 Differences in psoriasis severity and exposure to immunomodulatory therapies between cigarette smokers and nonsmokers: observations from the Psoriasis Longitudinal Assessment and Registry in patients with moderate to severe psoriasis**  
J. Walsh, F. Kerdel, G. Krueger and D. Amato
- P50 Red scrotum syndrome: a clinicopathological study**  
T. Narang, S. Dogra, M.S. Kumaran and U.N. Saikia
- P51 A clinical audit of the effect of targeted advice and vitamin D supplementation on serum vitamin D levels in patients with melanoma**  
S. Field, J. Davies, A. Mitra, H. Peach, D. Dewar and J.A. Newton-Bishop
- P52 Psoriasis, comorbidities and lifestyle: what is the patient's understanding of it?**  
S.H. Foo, G. Stewart, T. Michelle and E. Ladoyanni
- P53 Do dermatologists really know the costs of the investigations they request? A survey of dermatologists in practice**  
F. Latheef and M. Shah
- P54 Fatigue as a symptom in psoriasis and psoriatic arthritis**  
M. Sadlier, R. Fitzgerald, P. Collins, S.C.F. Rogers, O. FitzGerald, B. Kirby and A. Tobin
- P55 Patch testing practice in the U.K.**  
B.S. McDonald and D.A. Buckley
- P56 How are patients with actinic keratoses managed in primary care?**  
S. Sanyal, A. Holme and D. Kemmett

## Skin Cancer

- P57 Five-year recurrence rate of lentigo maligna after treatment with imiquimod determined using in vivo confocal microscopy**  
A. Kai, T. Richardson, A. Coleman, R. Mallipeddi and E. Craythorne
- P58 Incidence of primary cutaneous T-cell lymphoma in Wales**  
R. Abbott, S. Dojcinov, C. Aldridge and V. Piguet
- P59 Progress towards integrating a melanoma diagnostic index into a U.K. dermatology department quality dashboard**  
P. Gazzani, J. Rothwell, C. Kasparis and B. Gee
- P60 The treatment of cutaneous metastatic melanoma with topical diphencyprone**  
N. Spierings and V. Akhras
- P61 The perils of using national cancer surveys to reflect local departmental practices**  
N. Anjum, C. Coley and A.E. Haworth
- P62** Abstract withdrawn
- P63 The management of narrowly excised cutaneous squamous cell carcinomas**  
D. Jain, S. Verykiou, M. Vatve and S. Wahie
- P64 Electronic patient booking and quality measures in skin cancer management**  
G. Fremlin, A.P.J. Bray and D.A.R. de Berker
- P65 Two-week waits, adherence to referral guidelines, and rate of secondary malignancy in the suspected cancer clinic**  
E.E. Merika and L.A. Fearfield

## Therapy

- P66 Iontophoresis for hyperhidrosis: effectiveness of treatment**  
C. Sharpe, J.K. Schofield and N.C. Hepburn
- P67 Predictors of response to increasing the dose of etanercept: results of an audit**  
K. Aljefri, P.J. Hampton and N.J. Reynolds
- P68 Audit of potent topical steroid use among new psoriasis patients referred to a dermatology department**  
C. Reid, K.E. Eustace, C. Keating, R. Hughes, S. Verma, R.B.M. Barry, P. Collins, A. Lally and B. Kirby
- P69 Topical immunotherapy with diphenylcyclopropenone for alopecia areata: our experience**  
N.Y.Z. Chiang and A. Abdullah
- P70 Delusional infestation and patient adherence to treatment**  
A. Ahmed and A.P. Bewley
- P71 Review of the use of diphencyprone in the treatment of alopecia areata: the last 20 years in Glasgow**  
R.C. Lamb and S.C. Holmes
- P72 Pro forma improves compliance with NICE guidance in the assessment and management of atopic eczema in children under 12 years**  
K. Scharrer, K. Radley, K. Hussain, N.C. Hepburn and J.K. Schofield
- P73 Xeomin® vs. Botox® in the treatment of severe axillary hyperhidrosis**  
T. T. Lew, A. Francis, M. De Vos, N. Baksh and R. Morris-Jones

- P74 Use of botulinum toxin injections to treat notalgia paraesthetica**  
J. Collins, S. Kamath and J.R. Hughes
- P75 Inflammatory leg ulcers: do not forget compression**  
N. Clayton, C.L. Lowry and R.H. Bull
- P76 Tuberculosis screening of patients on biological therapies: linking clinical practice to national guidelines**  
P. Mahendram, M.A. Hack, R.G. Goodwin, T. Bale and A.V. Anstey
- P77 Cardiovascular safety in the ustekinumab Clinical Development Programme: final update with up to 5 years of follow-up**  
K. Reich, M. Leibold, C.E.M. Griffiths and P. Szapary
- P78 Targeted cognitive behavioural therapy is effective in reducing alcohol misuse in patients with moderate to severe psoriasis**  
O. Founta, K. Adamzik, C. Reid, A-M. Tobin, D. Hevey and B. Kirby
- P79 Traditional antiseptics show ineffective antistaphylococcal bactericidal activity**  
C. Leitch, A. Leitch and M.J. Tidman
- P80 Distinguishing between bioequivalence and bioavailability: the pitfalls of switching brands in ciclosporin prescribing**  
F. Latheef, S. Das and B.P. Walker
- P81 Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy vs. oral minocycline in patients with active vitiligo vulgaris**  
A. J. Kanwar, A. Singh and D. Parsad
- P82 Evaluation of the bactericidal activity of an antiseptic emollient wash formulation against Panton-Valentine leucocidin-producing Staphylococcus aureus**  
J. Gallagher, P. Rosher, J. Leeming and A. Hidalgo-Arroyo
- P83 White's tar paste as an outpatient-based treatment for psoriasis**  
R. Fitzgerald, K.E. Eustace, F. Carroll, A. Kavanagh, B. Kirby, P. Collins and A. Lally
- P84 Analgesia requirements in toxic epidermal necrolysis: unmeasured and unmet?**  
B. Moriarty, R. Lamb, A. Durack, C. May, C. Smith, C. Fagan, D. Creamer and S. Walsh
- P85 Long term prophylactic management of hereditary angio-oedema, a rare but important cause of referrals to dermatology**  
J.M. Kassim and C. Grattan
- P86 Our experience of transient elastography and Fibrotest® in monitoring patients taking methotrexate for psoriasis**  
M. Lynch, E. Higgins, P.A. McCormick, B. Kirby, A. Lally, S. Rogers, A. Vellinga, H. Omar and P. Collins
- P87 Therapy with rituximab for pemphigus and pemphigoid: a retrospective study of 103 patients**  
K. Heelan, S.R.A. Walsh and N.H. Shear
- P88 A prospective, double-blind, randomized controlled trial of folic acid supplementation vs. placebo in patients with chronic plaque psoriasis treated with methotrexate and effects on serum homocysteine**  
P.D. Yesudian, N. Hashim, A. Bharati, A. Alkali, R.B. Warren, T. Cox and R.A.G. Parslew

## WEDNESDAY 10TH JULY – SATELLITE SYMPOSIUM

TIME	PROGRAMME	ROOM
08:00 – 08:45	ALMIRALL LTD SATELLITE SYMPOSIUM	HALL 3A

### Old age, new evidence in dermatology

New, exciting evidence in older patients will be discussed with our 'Question Time' style expert panel including:

Hosted by Michael Barratt (writer, journalist and a former BBC television presenter)

**Professor Michael Cork**  
Dermatologist, University of Sheffield

**Professor Eggert Stockfleth**  
Dermatologist, Charité - Universitätsmedizin Berlin

**Professor Peter Passmore**  
Ageing and Geriatric Medicine, Queen's University Belfast

**Sheila Robertson**  
Dermatology Liaison Nurse Specialist

## WEDNESDAY 10TH JULY – SATELLITE SYMPOSIUM

TIME	PROGRAMME	ROOM
08:00 – 08:45	BEIERSDORF SATELLITE SYMPOSIUM	HALL 3B

### Hyperpigmentation – Facing the Challenge

CHAIR: Dr Yuliya Zielinski

**The cosmetic use of skin lightening agents: merits, challenges and controversies!**  
Dr Ophelia Dadzie, London

**4-n-butylresorcinol: a highly effective tyrosinase inhibitor that reduces hyperpigmentation**  
Dr Ludger Kolber, Hamburg

**Questions and Answers**  
Dr Yuliya Zielinski

## WEDNESDAY 10TH JULY – SATELLITE SYMPOSIUM

TIME	PROGRAMME	ROOM
13:15 – 14:15	JANSSEN SATELLITE SYMPOSIUM	HALL 3B

### Treating the whole patient : The joint approach Should dermatologists and rheumatologists work more closely together to treat the whole patient?

Join us for a lively discussion looking at patient case studies.

CHAIRS: Dr Sarah Jarvis, resident Doctor on TV's the One Show

**Panel members:**  
Dr Ruth Murphy, Dermatologist, Nottingham  
Dr Ira Pande, Rheumatologist, Nottingham  
Dr Mark Goodfield, Dermatologist, Leeds  
Prof Dennis McGonagle, Rheumatologist, Leeds  
Dr Tony Downs, Dermatologist, Exeter  
Dr Richard Haigh, Rheumatologist, Exeter

## WEDNESDAY 10TH JULY – SATELLITE SYMPOSIUM

TIME	PROGRAMME	ROOM
13:15 – 14:15	MEDA PHARMACEUTICALS SATELLITE SYMPOSIUM	HALL 11A & B

### Current Controversies in the Management of Actinic Keratoses Debate

CHAIR: Dr Colin Fleming, Dundee

**Welcome, Introduction & Audience Voting**  
Dr Colin Morton

1st Proposer: **Treat the entire field - clinical and sub-clinical lesions**  
Professor Eggert Stockfleth, Berlin

1st Opposer: **Treat what you see or should you treat at all?**  
Professor Rino Cerio, London

2nd Proposer: Dr Chris Bower, Exeter

2nd Opposer: Dr Jonathan Bowling, Oxford

**Conclusions & Audience Voting**  
Dr Colin Fleming



## WEDNESDAY 10TH JULY – SATELLITE SYMPOSIUM

TIME	PROGRAMME	ROOM
13:15 – 14:15	ABBVIE SATELLITE SYMPOSIUM	HALL 3A

### Refining our approach to the management of psoriatic disease

- Are you interested in changing clinical practice and improving the psoriatic patient pathway?
- Do you want to help develop practical tools to overcome some of the challenges we face in joint dermatology–rheumatology working?

Join a distinguished multidisciplinary faculty in this brainstorm as we begin to develop a simple useable tool to facilitate collaborative working in line with NICE guidelines and Quality Standards.

#### Faculty

**Dr Richard Warren**  
Dermatologist (Manchester)

**Dr Joyce Leman**  
Dermatologist (Glasgow)

**Dr Hector Chinoy**  
Rheumatologist (Manchester)

**Dr Laura Coates**  
Rheumatologist (Leeds)

## WEDNESDAY 10TH JULY – SATELLITE SYMPOSIUM

TIME	PROGRAMME	ROOM
18:15 – 19:00	NOVARTIS SATELLITE SYMPOSIUM	HALL 3A

### Psoriasis in depth: A stratified approach to treating psoriasis

CHAIRS: Professor Nick J Reynolds, Institute of Cellular Medicine, Newcastle University, UK.

#### Right patient, right drug, right time

Dr Richard Warren, Salford Royal Foundation Hospital, UK  
*Dr Warren assesses the potential of personalised treatment to overcome the limitations of current therapies.*

#### The role of IL-17 in psoriasis and inflammatory arthritides

Dr David Lee, Novartis Institutes for BioMedical Research, Basel, Switzerland.  
*Dr Lee considers recent immunological research and insights that could lead to new therapeutic targets.*

#### Audience questions

Professor Nick J Reynolds.  
*The panel share their experience and answer questions from the audience.*

## WEDNESDAY 10TH JULY – SATELLITE SYMPOSIUM

TIME	PROGRAMME	ROOM
18:15 – 19:00	LEO PHARMA SATELLITE SYMPOSIUM	HALL 3B


### Picato®, Actinic Keratosis (AK)\* and the Patient

- 18:15 **Current therapies for AK patients in the UK**  
Dr John Lear, Consultant Dermatologist, Manchester Royal Infirmary and Hope Hospital, Salford
- 18:25 **Picato® within AK\* treatment**  
Dr Sandeep Cliff, Consultant Dermatologist and Dermatological Surgeon, East Surrey Hospital, Surrey and Sussex Healthcare NHS Trust
- 18:40 **The Picato® patient experience**  
Dr Tony Downs, Consultant Dermatologist, Royal Devon and Exeter NHS Foundation Trust
- 18:55 **Question and answer session**  
Dr John Lear

\*\*Picato® is licensed for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.

# The ACC Exhibition Plan

Stand Number	Company
31	AbbVie Ltd
21	ABC Lasers
80	Activa Healthcare
17	Alliance Pharmaceuticals Ltd
68	Almirall Ltd
6	Aneurin Bevan Health Board Academic Dermatology
33	Athrodax Healthcare International Ltd
74	BAD Communications
44	BAD Historical Collection
63a	BAD Journals
53	BADBIR
42	Bayer Healthcare plc
18	Beiersdorf
73	Bio-Diagnostics Ltd
26	Blink Medical Ltd
28	Bristol Myers Squibb
32	British Skin Foundation
27	Brymill Cryogenic Systems (UK) Ltd
20	Celgene Ltd
63b	Clinical Services Unit
64	Clinique Laboratories LLC
22	CliniSupplies Ltd
63c	Community Dermatology & IFD
13	Crawford Healthcare Ltd
25	Cynosure UK Ltd
34	Derma UK Ltd
58	Dermal Laboratories Ltd
54	Dexcel Pharma Ltd
36	Diagenics Ltd
48	Dr. Hönle Medizintechnik GmbH
37	DreamSkin Health® Ltd
45	First Medical Staffing Solutions Ltd
60	Forest Laboratories UK Ltd
11	Galderma (UK) Ltd
66	Genus Pharmaceuticals Ltd
7	H&R Healthcare Ltd
85	Heine Optotechnik
46	Intrapharm Laboratories Ltd
70	Janssen
71	Johnson & Johnson Ltd
69	L'Oreal - La Roche Posay
14	LEO Pharma
41	London Dermatopathology
19	Meda Pharmaceuticals Ltd
47	medac GmbH
55	Mölnlycke Health Care
61	MSD (Diprobase)
65	Novartis Pharmaceuticals UK Limited
78	Pern Consumer Products Ltd
63	Pfizer Ltd
59	Reckitt Benckiser UK
12	Roche Products Ltd
52	RSKPHARMA Ltd
62	Schuco
77	SilDerm Ltd
79	Special Interest Groups
56	Spirit Healthcare
49	STD Pharmaceuticals
15	Stiefel, a GSK Company
3	Typharm Ltd
24	Wiley
23	Wisepress Medical Bookshop
43	World Congress on Cancers of the Skin 2014



Stand Number	Company
PSG6	Alopecia UK
PSG12	Behcets Syndrome Society
PSG15	British Association of Skin Camouflage
PSG17	Caring Matters Now
PSG5	Changing Faces
PSG4	Ehlers Danlos UK
PSG13	Golin Syndrome Group
PSG2	Ichthyosis Support Group
PSG14	Latex Allergy Support Group
PSG16	Nodular Prurigo International
PSG18	Psoriasis & Psoriatic Arthritis Alliance
PSG11	SKCIN
PSG3	Skin Camouflage Network
PSG20	Skincare Cymru
PSG8	The Hyperhidrosis Support Group
PSG9	The Psoriasis Association
PSG1	UK Dermatology Clinical Trials Network
PSG7	Vitiligo Society
PSG19	Worldwide Lichen Sclerosus
PSG10	Xeroderma Pigmentosum Support Group



93rd Annual meeting  
of the British Association  
of Dermatologists

### AbbVie Ltd

**Stand Number: 31**

Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, SL6 4XE  
 Phone: 01628 773 355  
 Contact: Chris Barton  
 Email: christopher.barton@abbvie.com  
 www.abbott.com

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and capabilities of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world's most complex and serious diseases.

In 2013, AbbVie will employ approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit [www.abbvie.co.uk](http://www.abbvie.co.uk)

### ABC Lasers

**Stand Number: 21**

Duxford Business Centre, Hill Farm Road, Whittlesford, Cambridge, CB22 4QT  
 Phone: 0845 1707 788  
 Contact: Guy Goudsmit  
 www.abclasers.co.uk

ABC Lasers part of Alma Lasers is the leading supplier of aesthetic, dermatological and surgical technologies. Alma Lasers is recognized by industry practitioners for its whole-hearted commitment and complete solutions to professional practices. Alma Lasers provides dermatologists, plastic surgeons and other medical professionals a non-invasive solution for nearly every treatment.

### Activa Healthcare

**Stand Number: 80**

1 Lancaster Park, Needwood, Burton on Trent, DE13 9PD  
 Phone: 01283 576 800  
 Contact: Nicki Haynes  
 Email: nickihaynes@activahealthcare.co.uk  
 www.activahealthcare.co.uk

When Activa Healthcare launched the new debridement product, **Debrisoft®**, they warned nurses to 'prepare to be amazed'. In fact, **'prepare to be amazed'** has proven to be an understatement!

**"Works like magic", "Incredible results", and "Absolutely outstanding"** are just some of the reactions after using **Debrisoft®**.

Are you **PREPARED** to visit Activa's Stand?

### Alliance Pharmaceuticals Ltd

**Stand Number: 17**

Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB  
 Phone: 01249 466 966  
 Contact: Laura Burgess  
 Email: info@alliancepharma.co.uk  
 www.hydromol.co.uk / www.alliancepharma.co.uk

The Hydromol® range of products includes ointments (3 in 1), creams and bath additives. These products are principally used in the UK to treat common dry skin conditions such as Eczema and Psoriasis. These products are SLS free and can be used individually, or together as a Complete Emollient Therapy regime.

### Almirall Ltd

**Stand Number: 68**

1 The Square, Stockley Park, Uxbridge, UB11 1TD  
 Phone: 020 7160 2500  
 Contacts: Natalie Marley, Margarita Pifarre, Samantha Howell  
 Email: info.uk@almirall.com  
 www.almirall.com

Almirall is an international pharmaceutical company with the primary purpose to provide valuable medicines to you and future generations. With headquarters in Barcelona, Spain, Almirall have a strong international interest in Dermatology and research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing.

### Aneurin Bevan Health Board Academic Dermatology

**Stand Number: 6**

St Woolos Hospital, Academic Dermatology, Block C, Newport, NP20 4SZ  
 Phone: 01633 238 561  
 Contact: Jane Jones  
 Email: jane.jones14@wales.nhs.uk  
 www.academicdermatology.co.uk

Dermatology training, education and research through patient involvement.

### Athrodax Healthcare International Ltd

**Stand Number: 33**

Hawthorn Business Park, Drybrook, Gloucestershire, GL17 9HP  
 Phone: 01594 544 440  
 Contact: Vivien Johnson  
 Email: sales@athrodax.co.uk  
 www.athrodax.co.uk

Since 1976, Athrodax have supplied, serviced and maintained Waldmann UV therapy systems, exclusively throughout the UK and Ireland.

We can supply the largest product range to suit all needs and budgets from whole body and partial treatment systems to hand and foot treatment systems.

### British Association of Dermatologists Biologic Interventions Register (BADBIR)

**Stand Number: 53**

BADBIR, The University of Manchester, Rutherford House (Unit 1 FF), Manchester Science Park, 40 Pencroft Way, Manchester, M15 6SZ  
 Tel: 0161 306 1896  
 Contact: Kathleen McElhone – BADBIR Coordinator  
 Email: badbir@manchester.ac.uk  
 www.badbir.org

The BADBIR is a national register of patients receiving therapy for the treatment of moderate to severe psoriasis in the UK. Data is collected on patients treated with biologics or other systemic treatments (for control purposes). The primary aim of the register is to monitor the safety of biologic agents.

### BAD Communications

**Stand Number: 74**

Willan House, 4 Fitzroy Square, London, W1T 5HQ  
 Tel: 02073916094  
 Contact: Nina Goad  
 Email: comms@bad.org.uk  
 www.bad.org.uk

### BAD Historical Collection

**Stand Number: 44**

Willan House, 4 Fitzroy Square, London, W1T 5HQ  
 Contact: Dr Nick Levell  
 Email: nick.levell@nnuh.nhs.uk

### BAD Journals

**Stand Number: 63a**

Willan House, 4 Fitzroy Square, London, W1T 5HQ  
 Tel: 0207 391 6346  
 Contact: John Caulfield, Editorial Manager  
 Email: john@bad.org.uk  
 www.bad.org.uk

### Bayer Healthcare plc

**Stand Number: 42**

Bayer House, Strawberry Hill, Newbury, RG14 1JA  
 Tel: 01635 563147  
 Contact: Maya Vlahovic  
 Email: maya.vlahovic@bayer.com  
 www.canespro.co.uk

Canespro® Fungal Nail Treatment Set - New & unique fungal nail treatment using keratolytic properties of 40% urea ointment. Treat for only 2-3 weeks to get rid of the infected parts of the nail. Follow-up treatment with an antifungal cream is recommended after treatment with Canespro is completed.

### Beiersdorf

**Stand Number: 18**

2010 Solihull Parkway, Birmingham Business Park, Birmingham B37 7YS  
 Tel: 07432 71 81 50  
 Contact: Eve Townley  
 Email: Eve.townley@Beiersdorf.com  
 www.eucerin.com

Eucerin is at the heart of skin science for the confidence of healthy and radiant skin. Eucerin is preferred by dermatologists worldwide because it provides highly effective and reliable products for all specific skin conditions. The Eucerin® Research Centre in Hamburg unites over one hundred years of experience in skin research with state-of-the-art technology.

### Bio-Diagnostics Ltd

**Stand Number: 73**

Upton Industrial Estate, Rectory Road, Upton-Upon-Severn, Worcestershire, WR8 0LX  
 Tel: 01684 592 262  
 Email: enquiries@bio-diagnostics.co.uk  
 www.bio-diagnostics.co.uk

### Blink Medical Ltd

**Stand Number: 26**

1320 Solihull Parkway, Birmingham Business Park, Birmingham, B37 7YB  
 Tel: 0121 386 8433  
 Contact: Roger Tyler, Managing Director  
 Email: sales@blinkmedical.com  
 www.blinkmedical.com

Blink Medical was established in 2004 as the world's first dedicated manufacturer of high quality, single use surgical instruments. We supply instrumentation to many of the UK's leading dermatology departments and with a worldwide distribution network, covering 15 countries we are leaders in design, development and manufacture of fine instrumentation and customised instrument sets.

Visit us at stand 26.

### Bristol-Myers Squibb

**Stand Number: 28**

Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH  
 Tel: 07753 976 705  
 Contact: Christina Cockley  
 Email: christina.cockley@bms.com

At Bristol-Myers Squibb, we are committed to finding innovative medicines to combat serious diseases, and to getting them to patients in the UK and worldwide faster and more efficiently. We have a strong legacy in discovering and developing cancer medicines dating back 40 years and our researchers continuing pursuit of new strategies to answer the unmet needs of patients has resulted in the emergence of a robust pipeline of anti-cancer agents. Identification of specific targets has facilitated the creation of molecules designed for their potential to inhibit tumour growth, survival and metastasis.

In the next few years, we hope that our decades of cancer research will result in the development of innovative medicines to fight aggressive and previously drug-resistant tumours.



### British Skin Foundation

**Stand Number: 32**

Willan House, 4 Fitzroy Square, London, W1T 5HQ  
Tel: 0207 391 6341

Email: admin@britishskinfoundation.org.uk

www.britishskinfoundation.org.uk

The British Skin Foundation is the only UK based charity dedicated to funding research into all skin diseases.

### Brymill Cryogenic Systems (UK) Ltd

**Stand Number: 27**

54 Mayfield Ridge, Basingstoke, RG22 4RS

Tel: 01256 841 045

Contact: Steve Williams

Email: sales@brymilluk.com

www.brymill.co.uk

Brymill Cryogenic Systems has been the world leader in the design and manufacture of the Cryosurgical equipment for over 40 years.

Brymill UK now supplies a wider range of quality products including Ethicon Sutures, Electrosurgery, HeadLights, Binocular Loupes, Dermatoscopes, Single Use Disposable Instruments, Woundcare Products and Smoke Evacuation systems. And introducing the Swift Microwave Generator.

### Celgene Ltd

**Stand Number: 20**

1 Longwalk Road, Stockley Park, Hillingdon, UB11 1DB

Tel: 0208 831 8300

Contact: Tim Shaw

www.celgene.com

Celgene Corporation is a global biopharmaceutical company that is helping healthcare providers address serious conditions, such as cancer and immune-inflammatory diseases. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programmes. Together, these aspects form the core of our commitment to patients worldwide.

### Clinical Services Unit

**Stand Number: 63b**

Willan House, 4 Fitzroy Square, London, W1T 5HQ

Tel: 020 7391 6085

Contact: Tania von Hospenthal

Email: clinical@bad.org.uk

www.bad.org.uk

### Clinique Laboratories LLC

**Stand Number: 64**

73 Grosvenor Street, London, W1K 3BQ

Tel: 0870 034 6955

Contact: Julia Cox

Email: jucox@estee-lauder.co.uk

www.cliniquederms.com

Allergy Tested. 100% Fragrance Free. Dermatologist Developed

### Clinisupplies Ltd

**Stand Number: 22**

Qualitas House, 100 Elmgrove Rd, Harrow, Middlesex, HA1 2RW

Tel: 0208 863 4168

Contacts: Rishi Doshi / Ade Akindeinde

Email: marketing@clinisupplies.co.uk

www.clinisupplies.co.uk

Established in 2000, CliniSupplies is a UK based medical devices company specialising in the manufacturing and marketing of products for the primary and secondary healthcare sectors.

CliniSupplies is supported by dedicated and experienced employees with a deep understanding of the medical devices market. The result is a reputation of providing high quality medical devices that are fully compliant with strict UK Specifications.

### Community Dermatology & IFD

**Stand Number: 63c**

Willan House, 4 Fitzroy Square, London, W1T 5HQ

Tel: 0207 391 6346

Contact: John Caulfield

Email: john@bad.org.uk

www.bad.org.uk

### Crawford Healthcare Ltd

**Stand number: 13**

King Edward Court, King Edward Rd, Knutsford, Cheshire, WA16 0BE

Tel: 01565 654920

Contact: Karen Kennedy

Email: info@crawfordpharma.com

www.crawfordhealthcare.com

Crawford Healthcare, is a supplier of dermatology and wound care products covering a broad range of skin conditions. We are dedicated to developing and providing innovative treatment solutions to care and repair the skin, helping our bodies to maintain our number one natural defense system.

### Cynosure UK Ltd

**Stand number: 25**

The Old Barn Offices, Lower Mount Farm, Long Lane, Cookham, Berkshire, SL6 9EE

Tel: 01628 522 252

Email: jenny@cynosureuk.com

www.cynosureuk.com

Contact: Ben Saviger-Jones / Jenny Flood

Cynosure UK Ltd's modular lasers are market leading products offering the ultimate technology for applications such as hair removal in all skin types, skin rejuvenation, tattoo removal, treatment of pigmented/vascular lesions including facial and leg veins. Our range includes the more invasive treatments such as laser lipolysis, surgical cellulite clearance and fractional rejuvenation.

### Derma UK Ltd

**Stand Number: 34**

ARC Progress, Mill Lane, Stotfold, Bedfordshire, SG5 4NY  
Tel: 01462 733 500

Contact: Phil Carroll

Email: info@dermauk.co.uk

www.dermauk.co.uk

Derma UK is dedicated to the provision of high quality and cost-effective dermatological preparations to dermatologists, nurses and other medical Practitioners in the UK. Please come and visit our stand to discuss how we may be able to assist in generating some cash savings on your prescribing budgets.

### Dermal Laboratories Ltd

**Stand Number: 58**

Tatmore Place, Gosmore, Hitchin, SG4 7QR

Tel: 01462 458 866

Contact: Me Henrik Pyff

Email: info@dermal.co.uk

www.dermal.co.uk

2013 sees Dermal celebrate 50 years of successful topical innovation.

This extensive experience in developing highly effective, yet cosmetically elegant treatments for application to the skin, has benefitted millions of people for half a century.

Come and visit us on Stand 58 to hear more about our products and dermatology services.

### Dexcel Pharma Ltd

**Stand Number: 54**

7 Sopwith Way, Drayton Fields Industrial Estate, Daventry, Northants, NN11 8PB

Tel: 01327 316 858

Contact: Rob Callum

Email: deximune@dexcelpharma.co.uk

www.deximune.co.uk

Dexcel Pharma Ltd is the manufacturer of Deximune®, an alternative brand of ciclosporin which is bioequivalent to the leading brand whilst offering significant savings. Dexcel Pharma Ltd specialises in the discovery, development, manufacture and marketing of innovative formulations of successful, established, prescription drug molecules. Dexcel Pharma offers significant savings to the NHS.

### Diagenics Ltd

**Stand Number: 36**

South House 3, Bond Avenue, Bletchley, Milton Keynes, MK1 1SW

Tel: 01908 376 376

Contact: Jim Khambatta

Email: info@diagenics.co.uk

www.diagenics.co.uk

Diagenics will be showing the truestest patch test system, which allows the rapid application of 34 pre-dispensed patches and also Allergeaze, a comprehensive system of petrolatum allergens, & chambers and newly introduced Patchmap and Patchprotect to ensure the security of application of the chambers and the identity of the allergens.

### Dr. Hönle Medizintechnik GmbH

**Stand Number: 48**

Viktor-Frankl-Strasse 20, 86916 Kaufering, Germany  
Tel: +49-8191-30555-0

Contact: Petra Kleinhans

Email: medizin@drhoenle.de

www.drhoenle.de

Dr. Hönle Medizintechnik is specialized in the sales and service of high-quality UV irradiation devices for the treatment of skin conditions. The company also sells iontophoresis units for the treatment of hyperhidrosis. Thanks to ongoing exchanges of ideas and experiences with patients and partners we are constantly improving our products.

### DreamSkin Health® Ltd

**Stand number: 37**

The Melon Ground, Hatfield Park, Hatfield, Hertfordshire, AL9 5NB

Tel: 01707 228 688

Contact: Tony Wilson

Email: tony.wilson@dreamskinhealth.co.uk

www.dreamskinhealth.co.uk

Therapeutic clothing that provides symptomatic relief for sufferers of eczema.

- Retains Moisture: Reduces the unregulated loss of moisture caused by evaporation from damaged skin.
- Repels Irritants: Forms a barrier that prevents irritants from reaching the skin.
- Maintains Temperature Regulation: Restores the skin's natural temperature management process.

### First Medical Staffing Solutions Ltd

**Stand Number: 45**

1.10 Challenge House, Sherwood Drive, Bletchley, Milton Keynes, MK3 6DP

Tel: 01908 533245

Contact: Lawrence Alexander

Email: Lawrence.Alexander@first-medical.co.uk

www.first-medical.co.uk

First Medical Staffing Solutions are the leaders in Dermatology Solutions for the NHS Hospitals. If you are a dermatologist and interested in a variety of full time, part time or ad hoc opportunities please register with us today!

Or if your dermatology department could use extra help, please visit our stand.

### Forest Laboratories UK Ltd

**Stand Number: 60**

Riverbridge House, Anchor Boulevard, Crossways Business Park, Dartford, DA2 6SL

Tel: 01322 421800

Email: info@forest-labs.co.uk

www.forest-labs.co.uk

Forest Laboratories UK Limited sells prescription medicines and branded pharmaceutical products sold over-the-counter (OTC).

Exorex Lotion (*Coal tar solution 5% v/w cutaneous emulsion*) is a clinically proven treatment for psoriasis.

### Galderma (UK) Ltd

**Stand Number: 11**

Meridien House, 69-71 Clarendon Road, Watford, WD17 1DS  
Tel: 01923 208 950  
Email: info.uk@galderma.com  
www.galderma.com

### Genus Pharmaceuticals Ltd

**Stand number: 66**

Park View House, 65 London Road, Newbury, Berkshire, RG14 1JN  
Tel: 01635 568 400  
Contact: Eric Sharp  
Email: info@genuspharma.com  
www.genuspharma.com

Genus Pharmaceuticals is a medium sized pharmaceutical company committed to providing quality healthcare products and services, focusing on specialised therapy areas, providing a responsive and friendly service to our customers whilst helping to ensure a positive difference for patients. Our expertise lies in Dermatology and Parkinson's Disease, substance misuse and tuberculosis.

### H&R Healthcare Ltd

**Stand Number: 7**

3 Redcliff Road, Melton Park, Melton, Hull, HU14 3RS  
Tel: 01482 631606  
Contact: Mike Hoskins  
Email: info@hrhealthcare.co.uk  
www.hrhealthcare.co.uk

H&R Healthcare distribute dermatologically advanced products for wound, skin and scar care. Sorbion sana: highly absorbent, non-adherent dressing for sensitive skin Proshield: the only barrier cream indicated for intact and injured skin associated with incontinence. BAP scar care: a comprehensive range of scar care products. The gel leaves a non-shiny matt finish ideal for use under make-up.

### HEINE Optotechnik

**Stand Number: 85**

Kientalstraße 7, 82211 Herrsching, Germany  
Tel: +49 (0) 8152 – 380  
Contact: Mr Werner Kruttsch  
Email: info@heine.com  
www.heine.com

HEINE Optotechnik. Founded in 1946, family owned and today the world's largest exporter of primary, hand-held diagnostic instruments. HEINE products meet all international standards (ISO/CE). Research and development has created a solid and diverse technology base for continued quality and product leadership. Over 500 employees worldwide contribute to this success.

### Intrapharm Laboratories Ltd

**Stand number: 46**

The Granary, The Courtyard Barns, Choke Lane, Cookham Dean, Maidenhead, Berkshire, SL6 6PT  
Tel: 01628 771800  
Contact: Sunil Shaunak  
Email: SunilS@intrapharmlabs.com  
www.intrapharmlabs.com

Intrapharm have re-launched Terra-Cortril Ointment for exudative and secondarily infected eczema including atopic eczema, primary irritant dermatitis, allergic and seborrhoeic dermatitis. Terra-Cortril is a combination of two components - oxytetracycline and hydrocortisone. It does not contain any preservatives.

Please visit our stand 46.

### Janssen

**Stand Number: 70**

50-100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG  
Tel: 01494 567 567  
Contact: Raquel Alcobia  
Email: ralcobi@its.jnj.com  
www.janssen.co.uk

Janssen is one of the world's leading research-based pharmaceutical companies, with operations throughout the world. Janssen is part of the Johnson & Johnson family of companies and is committed to delivering innovative treatments that can make an important difference to the lives of patients with serious health conditions.

### Johnson & Johnson Ltd

**Stand Number: 71**

Foundation Park, Roxborough Way, Maidenhead, SL6 3UG  
Tel: 01628 822222  
Contact: Rebecca Bennett  
Email: rbennet5@its.jnj.com  
www.JnJ.com

### LEO Pharma

**Stand Number: 14**

Longwick Road, Princes Risborough, Bucks, HP22 9RR  
Tel: 01844 347 333  
Email: general.uk@leo-pharma.com  
www.leo-pharma.co.uk

LEO Pharma is a global pharmaceutical company dedicated to helping people achieve healthy skin. Headquartered in Denmark, with 4,600 employees in 61 countries our dermatological and thrombosis products are sold in over 100 countries. Being owned by the LEO Foundation, with no external shareholders, profits are re-invested to benefit patients.

Leo® ©Leo Pharma, UK. All Leo trademarks mentioned belong to the Leo Group

### London Dermatopathology

**Stand Number: 41**

50 Belsize Square, London, NW3 4HN  
Tel: 020 8090 5802  
Contacts: Dr Alistair Robson / Mr Cameron Niven  
Email: operations@ldpath.com  
www.ldpath.com

- Premium specialist reporting by a team of 10 dermatopathologists
- Competitive flat fee structure (up to 7 specimens)
- Courier collection anywhere in the UK
- Reports delivered securely by email and via SSL-encrypted website
- 24-48hr turnaround
- Second opinion from expert panel
- Privileged access to educational material

### L'Oreal – La Roche Posay

**Stand Number: 69**

255 Hammersmith Road, London, W6 8AZ  
Tel: 07554 116 971  
Email: jtaylor3@uk.loreal.com  
Contact: Juliette Taylor

Recommended by over 25,000 dermatologists. Sensitive skin specialist.

Launched in 2009 in the UK, La Roche-Posay is committed to Dermatology offering a wide range of adjunctive therapy products for the main reasons of consultation in Dermatology practice.

Since 2009 La Roche-Posay has achieved great success with the launch of Anthelios XL, the highest SPF rated photo protection, which is also now available on prescription.

We support patient and professional education events together with extensive research in the field of Dermatology.

### Meda Pharmaceuticals Ltd

**Stand Number: 19**

Skyway House, Parsonage Road, Takeley, Bishop's Stortford, CM22 6PU  
Tel: 0845 460 0000  
Email: info@medapharma.co.uk  
www.meda-psm.com

At Meda, we're constantly evolving our impressive product range. In the UK we currently have over 70 products, including many well-known prescription, pharmacy and cosmetic brands.

Our ever-expanding product portfolio covers a wide range of treatment areas from allergy, cardiology and dermatology, to oncology and sexual health.

Within Dermatology we have just launched Zyclara 3.75% Imiquimod Cream for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding.

### medac GmbH

**Stand number: 47**

Scion House, Stirling University Innovation Park, Stirling, FK9 4NF  
Tel: 01786 458 086  
Email: info@medac-uk.co.uk  
www.medac-uk.co.uk

medac is a German based pharmaceutical manufacturer with a growing number of branches around the world.

Metobject (methotrexate injection 50 mg/ml) was launched by medac and is indicated for the treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy.

### Mölnlycke Health Care

**Stand Number: 55**

Arenson Centre, Arenson Way, Dunstable, Bedfordshire, LU5 5UL  
Tel: 0800 7311 876  
Email: info.uk@molnlycke.com  
www.molnlycke.co.uk

Mölnlycke Health Care manufactures and markets a range of dermatology products for eczema, psoriasis and other dry skin conditions including; Epaderm® Ointment, Epaderm® Cream and Tubifast® Garments.

Molnlycke offers a product portfolio with which to meet the needs of health care professionals in hospitals and primary care organisations.

### MSD (Diprobase)

**Stand number: 61**

Hertford Road, Hoddeson, Hertfordshire, EN11 9BU  
Tel: 01992 455 423  
Contacts: Ellen Edwards, James Cotterell, Julie Dixon  
Email: julie.dixon@merck.com  
www.diprobase.co.uk

The Diprobase emollient range has been patient friendly for 30 years. The formulations are tried and trusted making it the UK's number 1 most GP prescribed emollient. Diprobase is an MSD – Consumer Care product.

Today's MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.

### Novartis Pharmaceuticals UK Ltd

**Stand Number: 65**

200 Frimley Business Park, Frimley, Surrey, GU16 7SR, United Kingdom  
www.novartis.co.uk

At Novartis, our goal is to provide high quality healthcare solutions to address the evolving needs of patients and society in the UK.

We believe that our dedication to innovation and our responsible approach will enable us to fulfil our mission to care for and provide high quality treatments for people with psoriasis.



### Pern Consumer Products Ltd

**Stand number: 78**

Quantum House, Hobson Industrial Estate, Burnopfield, County Durham, NE16 6EA  
Tel: 01207 279 401

Contacts: Manager: Lisa Runkee/  
External Business consultant: P Richardson  
Email: business\_support@pern-consumer.co.uk  
www.dermacool.co.uk

Pern Consumer products are featuring Dermacool – Menthol in Aqueous Cream BP, which is available in 0.5%, 1.0% & 2.0% strengths. Currently the range is available in 100g tubes; 450g pump dispensers and traditional 500g pots.

### Pfizer Ltd

**Stand Number: 63**

Walton Oaks, Dorking Road, Walton-on-the-Hill, Tadworth, KT20 7NS  
Tel: 07990 530081

Contact: Christine Ward  
Email: christine.ward@pfizer.com

PASI educational tool for dermatology nurses/SpRs/ Consultants to help to develop skills in scoring psoriasis as part of their daily assessments.

### Reckitt Benckiser UK

**Stand Number: 59**

Wellcroft House, Wellcroft Road, Slough, Berkshire, SL1 4AQ

Tel: 01753 217800  
Email: medicalaffairs@reckittbenckiser.com  
www.e45.com / www.rb.com

Reckitt Benckiser is a global company operating in health & personal care. The UK healthcare business has leading pharmaceutical products, including E45 Cream for the relief of eczema and dry skin conditions.

### Roche Products Ltd

**Stand Number: 12**

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Herts, AL10 9JU  
Tel: 01707 366 000

Contacts: Bryan Richardson / Richard Eaton / Georgina Wardell  
Email: bryan.richardson@roche.com /  
Richard.eaton@roche.com / Georgina.wardell@roche.com  
www.roche.co.uk

Roche is a globally leading biotech company with differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is the world leader in-vitro diagnostics and tissue based cancer diagnostics management. Roche's personalised healthcare strategy provides medicines and diagnostic which enables tangible improvements in the health, quality of life and survival of patients.

### RSKPHARMA Ltd

**Stand Number: 52**

335 City Road, London, EC1V 1LJ  
Tel: 0203 291 1916

Contact: Dr Hamidreza Khalatbari  
Email: info@rskpharma.co.uk  
www.rskpharma.co.uk

Dexem® Repair is a product line designed based on patented natural Bioactive complex to block harmful bacteria from attacking the irritated skin and targets the symptoms of eczema and other forms of irritated skin. This steroid-free product allows the irritated and eczematous skin to recover naturally without the constant stress from external factors. Dexem Repair has been dermatologically tested and suitable to use on children.

### Schuco

**Stand Number: 62**

Axis 4, Rhodes Way, Watford, WD24 4YW  
Tel: 020 8368 1642

Contact: James Watson  
Email: james.watson@schuco.co.uk  
www.schuco.co.uk

*At Schuco you'll find tomorrow's skin technology, today!*

Share our passion and expertise for innovative medical devices for dermatology and aesthetics including; imaging, detection and management of a variety of conditions from early detection of skin cancer to minor surgery and PRP (Platelet-Rich-Plasma).

### SilDerm Ltd

**Stand Number: 77**

DaneMill, Broadhurst Lane, Congleton, Cheshire, CW12 1LA

Tel: 01260 271666  
Contact: Aileen Cameron  
Email: aileen@silderm.com  
www.silderm.com

The development of all SilDerm's products is based on sound scientific and medical research and all products have proven effectiveness. The recent addition of our scar gel and spray range leads the way in the management of scars and burns.

### Special Interest Groups

**Stand Number: 79**

Willan House, 4 Fitzroy Square, London, W1T 5HQ  
Tel: 020 7391 6358

Email: conference@bad.org.uk  
www.bad.org.uk

### Spirit Healthcare

**Stand Number: 56**

Spirit House, Selbury Drive, Oadby, Leicester, LE2 5NG  
Tel: 01162 865000

Contact: Angelina Thorne  
Email: angelinat@spirit-healthcare.co.uk  
www.spirit-healthcare.co.uk

Spirit Healthcare (STAND 56) is dedicated to helping you improve patient outcomes, expanding treatment choices and maximising productivity. We have launched a new range of Photodynamic Therapy products including Ameluz® 5-aminolaevulinic acid gel licensed ALA, the BF-RhodoLED static lamp, and Ambulight ambulatory light source. Spirit Healthcare: A brighter future in dermatology.

### STD Pharmaceuticals

**Stand Number: 49**

Plough Lane, Hereford, HR4 0EL  
Tel: 01432 373555

Contact: Julie Halford  
Email: enquiries@stdpharm.co.uk  
www.iontophoresis.info

STD are the suppliers of iontophoresis machines worldwide and provide machines for hospitals & patients throughout the UK.

Julie Halford from the Hyperhidrosis Support Group provides a one-off training session on Hyperhidrosis and the use of iontophoresis machines within the hospital environment. For further details please contact her at the Hyperhidrosis Support Group: info@hyperhidrosisuk.org

### Stiefel, a GSK company

**Stand Number: 15**

GlaxoSmithKline, Stockley Park West, 1-3 Iron Bridge Road, Uxbridge, UB11 1BT

Tel: 0208 990 9000  
Contact: Geoff Holmes  
Email: Geoff.d.holmes@stiefel.com  
www.stiefel.com

**Stiefel, a GSK company**, is committed to advancing dermatology and skin science around the world in order to help people better achieve healthier skin. Stiefel's dedication to innovation, along with its focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as a world leader in the skin health industry.

To learn more about Stiefel, visit [www.stiefel.com](http://www.stiefel.com).

### Typharm Ltd

**Stand Number: 3**

14D Wendover Road, Rackheath Industrial Estate, Norwich, NR13 6LH

Tel: 01603 722 480  
Contact: Shauna Clark  
Email: shaunaclark@typharm.com  
www.typharm.com

Typharm Ltd is a UK company that specialises in marketing a range of pharmaceutical products for the treatment of various inflammatory and non-inflammatory skin conditions. Products include Haelan Tape, a moderately potent steroid, presented in an occlusive tape for the treatment of recalcitrant dermatoses including eczema, heel and finger fissuring as well as overgranulation.

### Wiley

**Stand Number: 24**

1 Oldlands Way, Bognor Regis, West Sussex, PO22 9SA  
Tel: 01243 843 294

Contact: Customer Service Department  
Email: customer@wiley.com  
www.wiley.com

Wiley is an international scientific, technical, medical and scholarly publisher with over 1,400 peer-reviewed journals and 1,500+ new books annually in print and online. Wiley publishes the BAD's journals, the British Journal of Dermatology and Clinical and Experimental Dermatology.

### Wisepress Medical Bookshop

**Stand Number: 23**

25 High Path, Merton Abbey, London SW19 2JL  
Tel: 020 8715 1812

Contact: Nadia Ahmed  
Email: bookshop@wisepress.com  
www.wisepress.com

Wisepress.com, Europe's leading conference bookseller, has a complete range of relevant books and journals which can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. We also have a comprehensive medical and scientific online bookshop with great offers.

### World Congress on Cancers of the Skin 2014

**Stand Number: 43**

WCCS 2014, Conference & Event Services,  
4 Fitzroy Square, London, W1T 5HQ

Tel: 020 7391 6343  
Email: wccs2014@bad.org.uk  
www.wccs2014.com

The World Congress on Cancers of the Skin (WCCS 2014) will allow physicians a unique opportunity to interact with a distinguished international faculty and learn about breakthrough discoveries in the prevention, diagnosis, and treatment of all types of skin cancer.



### Location Key

1. Arena and Convention Centre
2. Atlantic Tower by Thistle
3. Base2stay Liverpool
4. BridgeStreet Worldwide
5. Crowne Plaza Liverpool City Centre
6. Days Inn Hotel
7. Express by Holiday Inn Albert Dock
8. Hampton by Hilton Liverpool City Centre
9. Hard Days Night Hotel
10. Hilton Liverpool
12. Hotel Ibis
13. Hotel Indigo
14. Jurys Inn
15. Malmaison
16. Novotel Liverpool Centre
18. Radisson Blu Hotel Liverpool
21. Staybridge Suites
22. StayLiverpool Apartments
- ★ Gusto Restaurant and Bar
- ★ Blue Bar
- ★ The Athenaeum
- ★ St George's Hall

### Delegate Bags

The Conference & Events Department is aiming to limit the impact the Annual Meeting has upon the environment. Conferences and exhibitions provide a huge amount of waste and this year we aim to continue to implement measures to improve this. Following feedback from previous meetings delegates will be provided with a generic delegate bag (as illustrated). This bag is made from recycled plastic bottle and has the BAD Logo on the side. We have made a decision not to include a sponsor, date or annual meeting destination. This will enable you to reuse the bag for other annual meetings as well as other BAD meetings. We hope this will become your BAD 'Bag for Life'. If you have a bag from a previous annual meetings please bring it with you.



Don't forget your bag!

### Evaluation Form

This year's evaluation form will be on-line and all attendees will be sent a link after the meeting. Thank you in advance for taking the time to complete it, as it is an invaluable tool for us in organising future meetings.

### CES MEETINGS CALENDAR

#### SEPTEMBER 2013

##### DermDoc

Venue: Willan House, London  
Date: 30th September

#### OCTOBER 2013

##### Clinical Dermatology Update Meeting for Staff and Associate Specialist Doctors

Venue: Radisson Blu Manchester Airport Hotel  
Date: 10th – 11th October

#### OCTOBER 2013

##### Teledermatology Forum

Venue: Willan House, London  
Date: 17th October

#### NOVEMBER 2013

##### SpR Training Event

Venue: Willan House, London  
Date: 7th – 8th November

#### NOVEMBER 2013

##### British Cosmetic Dermatology Group (BCDG) 8th Annual Meeting

Venue: Willan House, London  
Date: 9th November

##### The Annual UK Dermatology Course for Consultants

Venue: Hilton Paddington Hotel, London  
Date: 29th – 30th November



Join our Facebook Group: Conference & Event Services from the BAD



Follow us on Twitter @ BritDermEvents

For Further Details on any of these meetings please contact:

- Conference & Event Services; 4 Fitzroy Square London W1T 5HQ
- Email: [conference@bad.org.uk](mailto:conference@bad.org.uk)
- Tel: 020 7391 6358









# XV WORLD CONGRESS ON CANCERS OF THE SKIN

**3-6 SEPTEMBER 2014  
EDINBURGH, SCOTLAND**

**Professor John Hawk**  
*Congress President*

**Professor Alex Anstey**  
*Congress Secretary-General*

Supporting Organisations



visit  
**[www.wccs2014.org](http://www.wccs2014.org)**  
for details